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ABSTRACT
This work focuses on how arrestin regulates trafficking and signaling of
the N-formyl peptide receptor (FPR), a G protein-coupled receptor (GPCR).
GPCRs are involved in almost all physiologic processes and numerous
pathologic processes.

There is an intimate relationship between GPCR

trafficking and signaling that controls many cellular processes. However, the
protein-protein interactions that control post-endocytic trafficking and signaling of
GPCRs are poorly understood.
Our previous reports demonstrated that three events take place upon FPR
activation in the absence of arrestins: accumulation of FPR in the perinuclear
recycling endosome, lack of FPR recycling and apoptosis.

All of these

phenotypes were rescued by reintroduction of arrestin-2 cDNA. We therefore
hypothesized that 1) FPR trafficking and signaling defects were linked and causal
and 2) specific regions of arrestin-2 regulate normal FPR trafficking and
signaling.
To address these hypotheses, we generated mutants of arrestin-2 that
were previously described or changed regions of similar amino acids to alanine.
vii

We then screened these mutants for the ability to rescue FPR-mediated
apoptosis. Subsequently, we examined the role of these arrestin mutants in FPR
trafficking. We found that two arrestin-2 mutants demonstrated altered binding to
adaptor protein (AP)-2.

Furthermore, FPR recycling was inhibited in the

presence of either arrestin-2 mutant or the absence of AP-2. We also examined
the role of Src kinase in FPR trafficking and signaling and determined that Src
kinase has two independent roles in FPR-arrestin-2 regulation: one that controls
FPR trafficking and one that mediated FPR signaling. Finally, we found that
different SH3-binding domains of arrestin-2 regulate FPR trafficking and signaling
independently. One arrestin-2 mutant did not rescue FPR-mediated apoptosis,
but did mediate normal FPR trafficking.

These results indicate that FPR

trafficking and signaling are coordinated processes, but may also be regulated
independently.
These studies have revealed novel aspects of arrestin-2 that regulate FPR
signaling and trafficking. We hope they will serve as a model for the regulation of
other GPCRs.

Furthermore, we hope these data are used to create small

molecule inhibitors to serve as experimental tools and chemotherapeutics to
better understand and treat diseases caused by defects in GPCR trafficking and
signaling.
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1 INTRODUCTION

1

1.1

GPCR Overview
G protein-coupled receptors (GPCR) are the most abundant cell surface

receptors in the human genome consisting of 600-1000 genes (Lander et al.,
2001; Venter et al., 2001).

They are involved in almost every physiologic

process and numerous pathologic processes. These include, but are not limited
to, the cardiac system (Rockman et al., 2002), immune system (Lombardi et al.,
2002), neurologic system (Premont, 2005), nephrogenic diabetes insipidus
(Barak et al., 2001; Oakley et al., 2001), human immunodeficiency virus and
acquired immunodeficiency syndrome pathology (Lehner, 2002) and breast
cancer metastasis (Muller et al., 2001).

This receptor family is currently the

target of greater than 50% of pharmacologic agonists (activators) and
antagonists (inhibitors) currently prescribed by physicians (Papasaikas et al.,
2003).
GPCRs are single proteins that range in size from 40-60 kDa. These
receptors span the cell membrane seven times with interconnecting intracellular
and extracellular loops.

Typically, receptor ligands bind on the extracellular

surface, inducing a conformational change in protein structure that transduces
cellular signals to secondary signaling components within the cell. GPCR ligands
include, but are not limited to, photons, ions, peptides, amino acid derivatives,
lipid derivatives and odorants.

One exception to these rules is the recently

discovered estrogen-binding GPCR, GPR30, which is located in the endoplasmic
reticulum (Revankar et al., 2005).

2

1.2

Life cycle of a GPCR
Recent reviews have extensively described the signaling and trafficking of

GPCRs (Ferguson, 2001; Luttrell and Lefkowitz, 2002; Pierce and Lefkowitz,
2001). To summarize, these receptors bind ligand extracellularly, changing their
conformation to an activated state that binds heterotrimeric G proteins
intracellularly and mobilizes a variety of secondary messengers. These second
messengers include, but are not limited to, calcium and cyclic-adenosine
monophosphate and have a multitude of effects depending on cell type and the
intracellular milieu.
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Figure 1.1. Life Cycle of a GPCR
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After

activation

of

G

protein

signaling

cascades,

GPCRs

are

phosphorylated at serine and threonine residues in the cytoplasmic, C-terminal
domain of the receptor and/or intracellular loops by receptor kinases.

This

phosphorylation lowers the receptor’s affinity for G proteins and increases its
affinity for arrestins. Arrestin binding to phosphorylated receptor sterically blocks
the association of G proteins with activated receptor, thereby effectively stopping
the G protein signaling cascade. This process is known as desensitization.
During or following desensitization, the receptor/arrestin complex is bound
by proteins of the internalization machinery including, but not limited to, adaptor
protein-2 (AP-2) (Kim and Benovic, 2002), clathrin (Goodman et al., 1997;
Krupnick et al., 1997a; Krupnick et al., 1997b) and dynamin (van Koppen, 2001).
After internalization, GPCR scaffolds form, which induce signaling through the
MAPK signaling cascades (extracellular signal-regulated kinase (ERK) 1/2 and cjun n-terminal kinase (JNK) 3) (Luttrell and Luttrell, 2003; Miller and Lefkowitz,
2001; Pierce et al., 2001).

Finally, after internalization and GPCR scaffold

signaling, the receptor/arrestin complex generally has one of two fates:
degradation or resensitization and recycling. These details are further outlined in
Figure 1.1.
1.3

G protein signaling
The G proteins form a heterotrimeric complex that initially tranduce signals

of ligand-activated GPCRs. The heterotrimeric complex consists of an α, β and γ
subunit. While there are currently 20 known forms of Gα, they have been divided
into four families based upon sequence similarity: Gαs, Gαi, Gαq and Gα12/13.
4

There are also 6 forms of Gβ and 11 forms of Gγ.

While heterotrimeric G

proteins may consist of any combination of subunits, they are classified based on
the identity of the Gα subunit (Lefkowitz, 1998). Members of the Gαs family
stimulate adenyl cyclase to increase production of cyclic AMP. Conversely, Gαi
members inhibit adenyl cyclase. Gαq members stimulate phospholipase Cγ, the
actions of which ultimately lead to a release of intracellular Ca++. The target
effectors of Gα12/13 remain poorly characterized (Gether and Kobilka, 1998;
Neves et al., 2002).
Typically, after GPCR ligand binding and conformational rearrangement,
G proteins bind the intracellular face of GPCRs. The α subunit exchanges its
currently bound GDP for GTP thereby activating the subunit. Binding leads to
dissociation of the Gα from the Gβ/γ subunits leading to activation of second
messengers via the Gα subunit. Over time, the Gα subunit hydrolyzes GTP to
GDP and becomes inactive. GTP-GDP cycling can be accelerated by regulators
of G protein signaling (RGS) (Willars, 2006). RGS inhibit Gα signaling by acting
as GTPase activating proteins. The Gβ/γ subunit remains attached to the cell
membrane (via lipid modifications) and activates phospholipase Cγ (PLCγ).
PLCγ cleaves phosphoinositol bisphosphate to generate diacylglycerol and
inositol triphosphate. These proteins can induce further signaling via calcium
mobilization, binding to ion channels or phosphorylation of downstream targets
(Gether and Kobilka, 1998).
After G protein signaling is initiated, ligand-bound GPCRs undergo
homologous or heterologous desensitization.
5

Homologous desensitization is

mediated by G protein-receptor kinases (GRK) (Ribas et al., 2006). This protein
family contains seven members and GRK2 and GRK3 are most commonly
involved within this process. Heterologous desensitization also occurs via protein
kinases A and C.

To mediate desensitization, kinases phosphorylate ligand-

activated GPCRs at serine and threonine residues within the cytoplasmic tail or
intracellular loops.

C-terminal phosphorylation lowers GPCR affinity for G

proteins and increases GPCR affinity for arrestins. Arrestin (discussed below)
binding sterically blocks receptor binding to G proteins. This effectively stops
GPCR signaling through heterotrimeric G proteins.
1.4

GPCR signaling through arrestin
Although GPCRs were originally thought to signal solely through activation

of heterotrimeric G proteins, it is now known that non-G protein signaling occurs
via arrestin binding of GPCRs (Hall and Lefkowitz, 2002; Miller and Lefkowitz,
2001; Pierce et al., 2001; Reiter and Lefkowitz, 2006). Stimulation of GPCRs
with cognate ligands can lead to activation of Src kinase (Luttrell and Luttrell,
2004), extracellular signal-regulated kinase (ERK) 1/2 (Kim et al., 2005), p38
(Sun et al., 2002), c-jun n-terminal kinase (JNK) 3 (Miller et al., 2001) and NF-ΚB
(Gao et al., 2004). While these processes are activated by G protein signaling
they are also regulated by arrestins and are found within GPCR-arrestin
scaffolds. Activation of GPCRs through signaling scaffolds allows proper control
of spatial and temporal events while minimizing signaling crosstalk.

These

secondary signaling cascades control cellular processes such as proliferation
and migration (Luttrell and Luttrell, 2004).
6

Recent examples of arrestin regulation of GPCR signaling includes
arrestin-2 binding to calmodulin (Wu et al., 2006) and its translocation to the
nucleus (Beaulieu and Caron, 2005).

While the function of the arrestin-

2/calmodulin complex is currently unknown, but could have far reaching effects,
the latter is better understood.

Arrestin translocates to the nucleus after

activation of the δ- and κ-opioid receptors. In the nucleus, arrestin complexes
with p300 and CREB leading to acetylation of histone H4 that modulates
chromatin organization and enhances gene transcription.
1.5

GPCR trafficking and Rab GTPases
Upon activation of GPCRs, a number of proteins can be recruited to the

plasma membrane to aid internalization of activated GPCRs from the cell surface
(Bockaert et al., 2004a; Bockaert et al., 2004b). While it was believed earlier that
many or all GPCRs were dependent on the same families of molecules to
mediate internalization, more recent reports have described a variety of
determinants for GPCR internalization (Marchese et al., 2003). For example,
GPCRs can move into clathrin-coated pits or undergo clathrin-independent
internalization. Such GPCRs are dependent upon dynamin (Zhang et al., 1996),
AP-2 (Laporte et al., 2002), arrestin (Kohout et al., 2001) or ARF6 (Claing et al.,
2001). Other GPCRs are dependent upon none of these factors. At this time, it
remains unclear which proteins are utilized for N-formyl peptide receptor (FPR)
endocytosis.
After removal from the cell surface, endosomes formed during
internalization need to be directed to different locations for further processing.
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These cellular functions are controlled in part by the Rab GTPases, including
Rab4, 5, 7 and 11 (Rosenfeld et al., 2002). Similar to heterotrimeric G protein
complexes, these GTPases cycle between a GTP-bound form that is an active
protein and a GDP-bound state that is primarily inactive. GTP-GDP cycling is
regulated by GTP hydrolysis to GDP and release of GDP to bind GTP. These
reactions are aided by accessory proteins that regulate the rate of GTP binding
or GTP hydrolysis. Understanding the Rab GTPase pathway allows investigators
to examine the location of GPCRs at specific times of GPCR processing.

Rab5
Rab5
Rab7

coated
endosome

Rab4

Plasma membrane
Rab11

early
endosome

Late
endosome

Rab11

Rab11

Recycling
endosome

Rab7

Lysosome

Nucleus

Figure 1.2. Rab GTPases control GPCR trafficking.

Generally, endosomes derived from the plasma membrane contain Rab5
and are indicative of early endosomes. Some GPCRs are dependent upon Rab5
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for internalization (Seachrist et al., 2000), while there are some that do not
require Rab5 for internalization, but do colocalize with Rab5 at later time points
(Holmes et al., 2006). After internalization, GPCRs follow three main pathways.
They can translocate to 1) a Rab4-positive endosome indicative of an early
recycling pathway, 2) a Rab7-positive endosome that will lead to degradation of
the cargo by the lysosome or 3) a Rab11-positive endosome indicative of a late
recycling pathway (Rosenfeld et al., 2002). This model is summarized in Figure
1.2.
1.6

Arrestin Overview
There are four arrestins found within the human genome: arrestin1-4.

Arrestin1 (also known as visual arrestin) is found in rod cells of the eye and
mediates desensitization of rhodopsin, a GPCR responsible for vision. Arrestin4
(also known as x-arrestin or cone arrestin) is found within cone cells of the eye.
Arrestin-2 and 3 (also known as β-arrestin1 and β-arrestin-2, respectively) are
ubiquitously expressed in humans. While knockout mice for both arrestins do not
survive past early embryonic stages, knockout mice of either arrestin-2 or 3 yield
normal phenotypes although they are deficient in responses such a blood
pressure regulation (Conner et al., 1997). While this suggests that these two
arrestins are functionally redundant, this may not be the case. For example,
JNK3 binds arrestin-3 and is activated by GPCR-arrestin signaling scaffolds
(McDonald et al., 2000), whereas the same has not been proven with respect to
arrestin-2.
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Arrestin-2 (the focus of this study) is a cytosolic protein consisting of 418
amino acids. The structures of visual arrestin and arrestin-2 have been solved
by X-ray crystallography (Han et al., 2001; Hirsch et al., 1999), shown in Figure
1.3). The three-dimensional structure of arrestin consists of two groups of beta-

Figure 1.3. The 1.9 angstrom structure of arrestin-2. Taken from Han et al., 2001

pleated sheets. These two groups are referred to as the N domain (amino acids
8-180) and the C domain (amino acids 188-362). The remaining amino acids
form a C-terminal “tail” that interacts with both groups of beta-pleated sheets.
This “tail” is thought to move freely from the rest of the structure as it is not
detected during crystallography studies.
Before receptor activation, phosphorylation and arrestin binding, arrestin is
in a basal state with the C-terminal tail folded into the body of the structure. This
structure is maintained by hydrophobic residues within the “tail” of arrestin which
interact with corresponding hydrophobic residues within the beta-pleated sheets
and helix I. The structure is stabilized by hydrogen bonding between Arg175,
10

Asp 30, Asp296, Asp303 and Arg382 and is referred to as the “polar core”
(Figure 1.4). Critical to maintenance of this basal structure is Arg175 (Arg179 in

Figure 1.4. The polar core of arrestin. Taken from Vishnivetskiy et al., 1999

arrestin-2 and Arg180 in arrestin-3).

Mutagenesis of this residue (Arg→Glu)

confers the ability of arrestin to bind to non-phosphorylated GPCRs (Kovoor et
al., 1999; Vishnivetskiy et al., 1999). Hence, this region is also thought to sense
the phosphorylation state of GPCRs.
Upon activation of GPCRs and subsequent phosphorylation of their Ctermini, the following sequence of events for arrestin activation is thought to take
place based upon X-ray crystallography and mutagenesis studies.
excellent review of this topic, see (Gurevich and Gurevich, 2004).

For an
First, the

phosphorylated residues of receptor are drawn to positively charged lysine
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residues in the N domain of arrestin (Lys14 and Lys15 in arrestin-2). Interaction
of phosphorylated GPCRs with these residues causes the β strand of the N
domain to shift. This destabilizes the hydrophobic interaction between the “tail”
of arrestin and the N domain. The “tail”, now detached from the N domain forms
and initial opening of the arrestin molecule which allows the “tail” to interact with
accessory proteins. The phosphorylated C-terminus of the receptor is directed to
the phosphate sensor of arrestin (Arg175). These phosphates disrupt hydrogen
binding within the “polar core” allowing high affinity binding of arrestin and ligandactivated, C-terminal phosphorylated GPCRs.
1.7

Arrestin regulation of GPCR trafficking and signaling
Arrestins are cytosolic proteins originally thought only to mediate

desensitization of G protein signaling via GPCRs.

Subsequently, it was

demonstrated that arrestins could mediate GPCR internalization and regulation
of GPCR signaling scaffolds. It is currently known that arrestins bind numerous
proteins, including AP-2, clathrin, ERK1/2, and Src kinase to mention a few
(Luttrell and Luttrell, 2003; Luttrell and Luttrell, 2004; Miller and Lefkowitz, 2001;
Pierce and Lefkowitz, 2001; Pierce et al., 2001; Reiter and Lefkowitz, 2006)
(Figure 1.5). These accessory proteins assist arrestin with both the spatial and
temporal control of GPCR signaling.
Arrestin mediates internalization of many GPCRs such as the β2-AR and
angiotensin II (Type 1A) (AT1AR) receptors (Kohout et al., 2001). However, this
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Figure 1.5. Arrestin binding partners. Taken from Lefkowitz and Shenoy, 2005

is not the case for all GPCRs. For example, the FPR internalizes in an arrestinindependent (Vines et al., 2003) manner as does the m2-muscarinic
acetylcholine receptor (m2-AChR) (Pals-Rylaarsdam et al., 1997).

However,

while the proteins that mediate FPR internalization remain unclear, m2-AChR
internalization is dependent upon ADP-ribosylation factor 6.
Arrestin binding to both clathrin and AP-2 is integral to internalization of
certain GPCRs. Clathrin binds arrestin at the LIELD sequence from amino acid
residues 378-382. When this region is deleted from arrestin-2, clathrin binding is
diminished and internalization of the β2-AR is inhibited (Krupnick et al., 1997a).
With regards to AP-2, there are numerous binding sites within the arrestin-2 “tail”,
including amino acids Phe391, Arg393, Arg395, Lys397, Met399 and Lys400
which regulate binding to AP-2 and β2-AR internalization (Kim and Benovic,
2002; Milano et al., 2002).

Additionally, Asp385 and Phe388 demonstrate

decreased binding to AP-2 (Schmid et al., 2006), although the physiologic
consequence of these sites have not yet been determined.
The kinases, Src kinase and ERK1/2 also have roles with arrestin in
GPCR internalization. Src kinase phosphorylation of dynamin is required to allow
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dynamin to “pinch off” clathrin coated pits at the cell membrane and mediate
internalization of the β2-AR (Ahn et al., 1999).

Additionally, AP-2 must be

phosphorylated on tyrosine residues by Src kinase to release AP-2 from arrestin
and mediate internalization of the AT1AR (Fessart et al., 2005). In the context of
this receptor, both binding and release of AP-2 by arrestin are required to
internalize the AT1AR. Finally, ERK1/2 phosphorylation of Ser412 in the “tail” of
arrestin mediates internalization of the β2-AR (Lin et al., 2002; Lin et al., 1997).
When a constitutively phosphorylated form of arrestin-2 (S412D) was
overexpressed in cells, arrestin-2 could not change to its active state and
internalization was inhibited.
GPCR non-G protein signaling is also regulated by arrestin and its
interaction with accessory proteins. For example, ERK1/2 activation is mediated
through arrestin binding to GPCRs and G protein-mediated pathways. In one
study, it was determined that ERK1/2 activation via β2-AR or AT1AR stimulation
exhibited two individual phases (Shenoy et al., 2006; Shenoy and Lefkowitz,
2005). Pertussis toxin (which inhibits heterotrimeric G proteins), decreased the
early activation phase of ERK1/2. However, down-regulation of arrestins using
siRNA decreased the prolonged, latent phase of ERK1/2 activation while leaving
the former intact. Furthermore, it is thought that ERK1/2 activation via G protein
signaling pathways leads to phospho-ERK1/2 translocation to the nucleus where
it can induce changes in transcription (Tohgo et al., 2002). On the other hand,
ERK1/2 activation within the confines of a GPCR-arrestin scaffold retains
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phospho-ERK1/2 within the cytosol to activate other downstream effectors. The
cellular effects of the latter are unknown at this time.
Arrestin binding to Src kinase is essential to ERK1/2 activation within the
context of the β2-AR (Luttrell et al., 1999). Mutation of SH3-binding domains
within arrestin leads to decreased Src kinase binding upon receptor activation.
Additionally, these mutations led to decreased ERK1/2 phosphorylation upon
stimulation of the β2-AR and 5-HT serotenergic receptors. However, stimulation
of the AT1AR in the presence of the Src-binding deficient arrestin mutant yielded
no alteration in ERK1/2 phosphorylation.
Finally, ERK1/2 itself is important to GPCR-mediated ERK1/2 activation.
S412 of arrestin-2 is thought to be critical to activation of arrestin function.
Phosphorylation of this serine residue is regulated by ERK1/2.

In its

phosphorylated form, arrestin-2 is considered to be in an inactive state. When
unphosphorylated, arrestin can mediate many GPCR functions. Two mutants of
arrestin that mimic these constitutive states (S412D and S412A, respectively)
were overexpressed in the context of β2-AR activation. S412A had no effect on
β2-AR-mediated ERK1/2 activation, whereas the S412D mutant decreased
ERK1/2 phosphorylation (Luttrell et al., 1999). Hence, ERK1/2 activation through
GPCRs is regulated by the phosphorylation state of arrestin-2 which is, in turn,
regulated by ERK1/2.
1.8

Clinical importance of GPCRs
Three examples of the importance of GPCRs from a clinical perspective

are their roles in nephrogenic diabetes insipidus (Barak et al., 2001), cardiac
15

pathology (Rockman et al., 2002) and breast cancer metastasis (Muller et al.,
2001). Nephrogenic diabetes insipidus is a disease in which the V2-vasopressin
receptor (V2R) cannot respond to stimulation from arginine vasopressin (AVP)
and mobilize cyclic-AMP. As a result, the kidney cannot concentrate urine as it
normally would and patients lose excess water. This loss can be on the order of
15 liters per day. While many V2R mutants have been studied, R173H is of note
(Barak et al., 2001). V2R (R173H) fails to bind AVP, but binds arrestin with high
affinity in the absence of ligand and is contained in endocytic compartments
Hence, V2R (R173H) was constitutively desensitized. When further mutations
were made within V2R (R173H) that interrupted receptor-arrestin binding, the
receptor returned to the cell membrane and was able to mobilize cyclic-AMP
normally.
Second, a common example for the role of GPCRs in human disease is
cardiovascular pathology. This is, in large part, due to the fact that the β2-AR is
involved in these processes and is the best studied GPCR to date although many
adrenergic receptors play roles. Excellent reviews can be found on the role of
the adrenergic receptors in heart disease (Lefkowitz et al., 2000; Rockman et al.,
2002).

As an example of the role of adrenergic receptors in heart disease,

constant adrenergic stimulation (via stress, cortisol or other activation of the
sympathetic nervous system) can lead to heart failure, characterized by left
ventricular dysfunction with a complex of symptoms relating to inadequate
perfusion and pulmonary congestion. It is currently hypothesized that adrenergic
activation over long periods of time leads to desensitization and down-regulation
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of adrenergic receptors. In addition, this may lead to mitogen-activated protein
kinase (MAPK) signaling via inappropriate receptors with the result being further
ventricular remodeling. Without these receptors, the heart does not beat with
adequate force to perfuse tissues properly. This leads to a never ending cycle of
more adrenergic stimulation with deleterious results.

Furthermore, while the

molecular mechanisms are currently not understood, beta-blockers including
metoprolol and carvedilol can reverse some of the aforementioned effects. Most
importantly, studies have shown that long-term use increases patient survival in
those suffering from both moderate (Packer et al., 1996) and severe heart failure
(Packer et al., 2001). Improvements in heart function include positive effects on
left ventricular contractile function and structural changes to the size and shape
of the heart.
Finally, the chemokine receptors, CXCR4 and CCR7 play a role in breast
cancer metastasis (Muller et al., 2001). In this seminal report, CXCR4 and CCR7
were demonstrated to be overexpressed in breast cancer cells. Additionally, the
cognate ligands for the respective receptors were found highly expressed in
lymph nodes, lung, liver and bone from human tissue samples and not in other
organs. These are the most common sites for breast cancer metastasis. When
breast cancer cells were injected into mice along with antibodies to CXCR4,
metastasis to the aforementioned organs was decreased compared to injection
of isotype antibodies.
It is clear from the above examples that an understanding of GPCR
function is critical to understanding disease and treating patient illnesses. With
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knowledge of the function of GPCRs in both health and disease, novel or
improved treatments can be designed to help patients with a myriad of diseases.
1.9

N-formyl peptide receptor
The N-formyl peptide receptor (FPR) is a chemoattractant GPCR found

commonly on macrophages and neutrophils (Prossnitz and Ye, 1997). It is one
of the best described chemokine/chemoattractant GPCRs and its functions in the
immune system include regulation of adhesion, chemotaxis, superoxide
production and degranulation (Prossnitz and Ye, 1997). This receptor can be
found in neuromuscular, vascular and endocrine tissues (Becker et al., 1998),
fibroblasts (VanCompernolle et al., 2003) and hepatic cells (McCoy et al., 1995)
although its role in these tissues is not well understood. Dysfunctional FPRs
have been associated with localized juvenile periodontitis in humans (Gwinn et
al., 1999).

Additionally, FPR expression correlates with the rapid growth of

human gliomas (Zhou et al., 2005). The classic FPR ligands are formylated
peptides generated by bacteria, including E. coli, which generates N-formylMethionyl-Leucyl-Phenylalanine (fMLF) (Migeotte et al., 2006). When bacteria
invade the body, the FPR controls neutrophil migration to the site of infection
where degranulation is initiated and invading bacteria is killed.
Additionally, the FPR induces ERK1/2 phosphorylation (He et al., 2001)
upon activation with ligand. ERK1/2 activation via FPR stimulation is thought to
be mediated primarily through G protein activation (Gripentrog and Miettinen,
2005). This was determined using mutants of the FPR that do not bind arrestin,
but can activate ERK1/2 upon FPR stimulation with translocation of activated
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ERK1/2 to the nucleus. It has recently been demonstrated that FPR activation
induces trafficking and signaling defects as well as apoptosis in the absence of
one of its activated state binding partners, arrestin (Revankar et al., 2004; Vines
et al., 2003).
1.10

Hypothesis
Initially, FPR recycling was inhibited in the absence of arrestins and FPR

accumulated in the Rab11, perinuclear recycling endosome (Vines et al., 2003).
FPR was also demonstrated to internalize in the absence of arrestins.
Furthermore, FPR activation in the absence of arrestins initiated apoptosis
(Revankar et al., 2004). Reconstituting wild-type arrestin-2, -3 or both to arrestindeficient cells expressing the FPR rescued both the trafficking and apoptotic
phenotypes.

In addition, inhibitors of Src family kinases and MAPKs (p38,

ERK1/2 and JNK3) rescued the apoptotic phenotype.
We propose that in the absence of arrestins, activated FPR internalizes
and merges with a Rab5-positive endosome. The receptor eventually transfers
to a Rab11-positive endosome indicative of the recycling compartment.
Normally, in the presence of arrestins, the receptor/arrestin complex would be
dissociated and the FPR would travel back to the cell surface. However, in the
absence of arrestins, the receptor accumulates in the Rab11-positive endosome
in a perinuclear location.

We hypothesize in this Rab11-positive signaling

compartment, FPR continuously activates signaling complexes (MAPKs) leading
to the initiation of apoptosis. This model is summarized in Figure 1.6.
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Figure 1.6. Current model of FPR trafficking and signaling.

Based on these findings, we proposed two major hypotheses. First, we
hypothesized that FPR signaling and trafficking defects were both causal and
linked. Second, we hypothesized that specific regions of arrestin, which bind
other proteins within GPCR-arrestin scaffolds were responsible for regulating
these phenotypes. The following studies address both of these hypotheses and
elucidate mechanisms for arrestin in FPR trafficking and signaling. Our results
demonstrate novel roles for AP-2, AP-1 and Src kinase in FPR-arrestin signaling
and trafficking that may lead to the development of novel chemotherapeutics for
treatment of cancer metastasis.
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2.1

ABSTRACT
G protein-coupled receptors (GPCRs) are integral to cellular function in

nearly all physiologic and numerous pathologic processes. GPCR signaling is an
intricate balance between receptor activation, inactivation (desensitization and
internalization) and resensitization (recycling and resynthesis). While much is
known regarding the first two processes, the latter has not been as thoroughly
studied. To better understand the process of GPCR post-endocytic trafficking,
we focused on the N-formyl peptide receptor (FPR), a chemoattractant receptor
found primarily on neutrophils and macrophages.

Previous studies have

demonstrated that, although FPR internalization occurs in the absence of
arrestins, FPR recycling is arrestin-dependent. Furthermore, FPR stimulation in
the absence of arrestins leads to receptor accumulation in recycling endosomes
and apoptotic signaling. In this study, we determined that the carboxy terminus
of arrestin-2 is critical for intracellular receptor trafficking and performed scanning
mutagenesis of this region to ascertain the mechanisms involved. Our results
reveal that two arrestin-2 mutants (F391A and K397A/M399A/K400A), at sites
known to be involved in AP-2 binding, fail to rescue the trafficking and signaling
defects observed in the absence of arrestins. Further results demonstrate that
AP-2 associates with the receptor-arrestin complex in recycling endosomes and
is required for proper post-endocytic trafficking of the FPR, as revealed by siRNA
knockdown of AP-2, which inhibits recycling of the FPR to the cell surface.
Finally, we observe that AP-1 is associated with the receptor-arrestin complex
under recycling-competent conditions, suggesting a transfer of receptors from
23

AP-2- to AP-1-associated vesicles.

This is the first study to demonstrate a

requirement for AP-2 in the post-endocytic trafficking of a GPCR and serves as a
model for future studies in GPCR trafficking and resensitization.
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2.2

INTRODUCTION
G protein-coupled receptors (GPCR) are involved in signaling in virtually

every part of the human body including cardiovascular (Penela et al., 2006),
immune (Lombardi et al., 2002) and neuronal systems (Premont, 2005).

An

important feature of GPCR signaling is the cycle of receptor activation,
desensitization,

internalization,

down-regulation/degradation,

recycling

and

resensitization. When these processes are interrupted, they can detrimentally
affect cellular migration (Moratz et al., 2004), proliferation and cell adhesion
(Luttrell and Luttrell, 2004). In the case of v2 vasopressin receptors, constitutive
desensitization and internalization leads to nephrogenic diabetes insipidus (Barak
et al., 2001).
GPCRs are activated by a myriad of ligands including, but not limited to,
peptides, amino acids and their derivatives, proteins, ions, lipids and photons.
Ligand-bound GPCRs activate heterotrimeric G protein signaling pathways,
resulting in calcium mobilization and changes in cyclic-AMP levels, and are
subsequently phosphorylated on intracellular domains by serine/threonine
kinases, which reduce receptor affinity for G proteins and increases receptor
affinity for arrestins.

Arrestin binding sterically blocks receptor-G protein

interactions,

effectively

thereby

terminating

G

protein

signaling,

while

simultaneously providing a scaffold protein that can coordinate the recruitment of
internalization machinery, leading to receptor sequestration (Miller and Lefkowitz,
2001). In this model, based primarily on studies of the beta2-adrenergic receptor
(β2-AR), the most thoroughly described GPCR, adaptor protein (AP)-2 and
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clathrin (Kim and Benovic, 2002) bind the carboxy terminus of arrestin, initiating
association with clathrin-coated pits and internalization. Arrestin-recruited Src
then phosphorylates dynamin, which pinches off the plasma membrane
invagination to form an endosome containing receptor, from which arrestin
rapidly dissociates (Ahn et al., 1999). Internalized β2-AR in the rab5-containing
early endosomal compartment, is then sorted to lysosomes (via a Rab7containing compartment) for degradation or to the cell surface (via Rab4-positive
endosomes) (Cao et al., 1999).
This classic pathway of GPCR internalization and post-endocytic
trafficking is, however, not observed with all GPCRs.

For example,

internalization of the m2-muscarinic acetylcholine receptor is not dependent on
either arrestin or clathrin, utilizing instead an ARF6-dependent pathway (Delaney
et al., 2002).

Similarly, the N-formyl peptide receptor (FPR) has been

demonstrated to internalize in the absence of arrestins using knockout cell lines,
in which β2-AR internalization is completely inhibited (Kohout et al., 2001; Vines
et al., 2003). In contrast to GPCRs that follow the rab4-mediated, rapid recycling
pathway or the rab7-mediated, lysosomal degradation pathway (Rosenfeld et al.,
2002), some GPCRs recycle via perinuclear Rab11-containing recycling
endosomes.

Such receptors include the FPR (Vines et al., 2003), v2

vasopressin receptor (Innamorati et al., 2001), somatostatin 3 receptor (Kreuzer
et al., 2001) and CXC chemokine receptor 2 (Fan et al., 2003). In many cases,
such GPCRs have been shown to recycle more slowly and form stable
complexes with arrestins, resulting in prolonged endosome-associated arrestin
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(Oakley et al., 2001; Tohgo et al., 2003; Vines et al., 2003). Although the stable
endosomal association of arrestin with receptors has been shown to be critical in
a second prolonged phase of ERK activation in the cytoplasm (Tohgo et al.,
2003; Tohgo et al., 2002), little is known regarding the role of arrestin in
regulating intracellular trafficking of GPCRs, particularly via the perinuclear
Rab11-containing recycling compartment.

Arrestin dissociation has however

been implicated as an essential step in the recycling and resensitization of the
bradykinin B2 receptor (Simaan et al., 2005). In cells lacking both arrestin-2 and
arrestin-3, recycling of the FPR is absent resulting in receptor accumulation in
perinuclear recycling endosomes, suggesting a critical role for arrestin in efferent
trafficking of the FPR from this compartment (Vines et al., 2003). Thus, arrestin
appears to mediate multiple aspects of GPCR trafficking.
Subsequent studies of FPR stimulation in arrestin-deficient cells revealed
that, in addition to a recycling defect, cells also underwent apoptosis (Revankar
et al., 2004). A requirement for receptor internalization was demonstrated using
a signaling-competent, internalization-defective mutant of the FPR. Furthermore,
apoptosis was prevented by MAPK and other signaling inhibitors. This led to the
hypothesis that the accumulation of ligand-activated FPR in recycling endosomes
results in aberrant signaling, which initiates apoptotic pathways culminating in
caspase activation. Based on the fact that both the trafficking and signaling
defects could be rescued by the re-introduction of either arrestin-2 or arrestin-3,
we

hypothesized

that

mechanistically linked.

these

two

apparently

distinct

defects

may

be

Because of the large number of arrestin-interacting
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proteins, we speculated that the absence of specific interactions might be
responsible for the observed defects. Therefore, in this study, we undertook a
mapping study to identify the sites within arrestin that when mutated, result in
aberrant signaling and trafficking. Our results reveal novel mechanisms in which
AP-2 specifically regulates efferent FPR trafficking from recycling endosomes.
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2.3

RESULTS

2.3.1 Rescue of FPR-mediated apoptosis by arrestin-2 domains.
We have previously described a requirement for arrestins in preventing
apoptosis resulting from activation of multiple GPCRs, including the FPR, IL8R/CXCR2 and Angiotensin II (Type 1A) receptor (Revankar et al., 2004).
Arrestins also play a critical role in the proper intracellular trafficking of GPCRs
such as the FPR, although FPR internalization does not require arrestin. To
better understand the role of arrestin-2 in FPR post-endocytic trafficking, we
sought to define the region(s) of arrestin-2 responsible for preventing FPRmediated apoptosis. To this end, we generated four constructs producing large
fragments of arrestin-2 (arr2): amino acids 1-186, 177-418, 319-418 and 1-382.
The structure of arrestin-2 is composed of two domains of beta-pleated sheets
and a C-terminal “tail” (Milano et al., 2002). Arr2-(1-186) contains the amino
terminal domain of beta-pleated sheets of arrestin-2; arr2-(177-418) contains the
carboxy terminal domain of beta-pleated sheets and the carboxy terminal “tail” of
arrestin-2; arr2-(319-418) contains the “tail” (amino acids 357-418) that acts as a
dominant-negative construct inhibiting β2-AR internalization (Krupnick et al.,
1997b). Arr2-(1-382) is a truncated form of arrestin-2 that has been previously
described as constitutively active with respect to receptor binding, displaying
binding to unphosphorylated, liganded receptors as well as phosphorylated,
unliganded receptors, receptor forms that wild type arrestin-2 does not bind (Key
et al., 2001; Key et al., 2003; Kovoor et al., 1999; Potter et al., 2002).
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Mouse embryonic fibroblasts (MEF) deficient in both arrestin-2 and -3, but
stably expressing the FPR (arr2-/-/3-/- FPR), were used to assess arrestin-2
mutants in the absence of competition from endogenous arrestins.

Arrestin-

deficient cells transiently transfected with the four GFP-fused arrestin-2
fragments, wild type arrestin-2 and empty GFP vector were assayed for
apoptosis upon FPR stimulation by evaluation of cell rounding. In a previous
report, cell rounding was demonstrated to correlate absolutely with classical
markers of apoptosis including annexin-V staining, caspase activation and
propidium iodide (PI) staining (Revankar et al., 2004). As shown in Figure 2.1,
unstimulated cells (expressing GFP, wild type or mutant arrestins) did not exhibit
significant cell rounding (<20-30%). On the contrary, 70-80% of fMLF-stimulated
cells expressing GFP alone exhibited a rounded cell phenotype, whereas cells
expressing wild type arrestin-2 were indistinguishable from unstimulated cells, as
previously described (Revankar et al., 2004). Furthermore, none of the four
expressed arrestin-2 domains were capable of preventing FPR-mediated
apoptosis, although the arr2-(177-418) showed a small reduction in the number
of rounded cells. Of the four arrestin mutants, arr2-(1-382) is the only domain that
demonstrated association with the FPR upon stimulation (as determined by
confocal fluorescence microscopy, unpublished data). This is consistent with
previous data that demonstrated colocalization of arr2-(1-382) with the FPR upon
receptor activation (Key et al., 2005) and binding to the FPR in reconstitution
assays (Key et al., 2003; Potter et al., 2002). These results demonstrate that the
binding of arrestin-2 alone is insufficient to prevent FPR-mediated apoptosis and
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furthermore that sequences within the carboxy terminus of arrestin-2 (amino
acids 383-418) are essential to prevent apoptotic signaling.

2.3.2 Rescue of FPR-mediated apoptosis by arrestin-2 tail mutants.
The tail of arrestin-2 contains recognition sites for multiple adapter and
signaling proteins, including clathrin (Goodman et al., 1997; Krupnick et al.,
1997a; Krupnick et al., 1997b), AP-2 (Kim and Benovic, 2002; Milano et al.,
2002) and ERK, which phosphorylates a serine at position 412 (Lin et al., 1997).
Based on the cell rounding results (Figure 2.1), we hypothesized the amino acids
in arrestin-2 responsible for suppressing FPR-mediated apoptosis lie within its
carboxy terminus.

To test this hypothesis, we generated nine mutants of

arrestin-2 using alanine-scanning mutagenesis and previously described
mutations (Figure 2.2).

Previously described mutations include arr2-F391A,

which demonstrates reduced AP-2 binding (Milano et al., 2002), arr2-4A, in which
K397, M399 and K400 have individually been shown to mediate AP-2 binding
(Kim and Benovic, 2002), arr2-∆LIELD, which results in reduced clathrin binding
(Goodman et al., 1997; Krupnick et al., 1997a; Krupnick et al., 1997b) and
S412D/S412A, which mimic the phosphorylated and unphosphorylated states of
arrestin-2, respectively (Lin et al., 1997).
GFP-fusions of the nine arrestin-2 tail mutants were tested for their ability
to prevent FPR-mediated apoptosis.

Following transient transfection, GFP-

expressing cells (representing transfected cells) were stimulated with fMLF and
scored for apoptosis by propidium iodide staining.
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Previous results have

demonstrated a direct correlation between cell rounding and PI staining in cells
undergoing FPR-mediated apoptosis (Revankar et al., 2004). Greater than 95%
of GFP vector- and arr2- (1-382)-expressing cells were PI positive upon fMLF
stimulation (Figure 2.3), consistent with cell rounding results (Figure 2.1).
Expression of wild type arrestin-2 and all mutants with the exception of the arr2F391A and -4A rescued cells from FPR-mediated apoptosis (Figure 2.3). All
transfected cells showed minimal PI staining in the absence of ligand stimulation.
To confirm that positive PI staining was the result of FPR-mediated apoptosis,
empty GFP, wild type arrestin-2, -(1-382), -F391A and -4A were treated with the
pan-caspase inhibitor, zVAD-FMK, prior to fMLF stimulation. Transfected cells
that underwent apoptosis in response to FPR stimulation failed to do so in the
presence of zVAD-FMK, demonstrating that the PI staining in the presence of the
arrestin-2 mutants F391A and 4A represents FPR-mediated, caspase-dependent
apoptosis (Figure 2.11).

2.3.3. Arrestin-2 mutants that rescue apoptosis do not inhibit FPR
internalization.
Previous results have demonstrated that receptor internalization, which
occurs via arrestin-independent mechanisms, is essential for FPR-mediated
apoptosis (Revankar et al., 2004).

Because AP-2 is required for the

internalization of certain GPCRs, we hypothesized that overexpression of
arrestin-2 mutants might inhibit FPR internalization, thereby preventing FPRmediated apoptosis. To this end, we measured FPR internalization for each
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arrestin mutant. We determined that the extent of FPR internalization varied
between 65-80%, with no significant difference between the extents (Figure 2.4)
or rate (unpublished data) of internalization for any of the arrestin constructs
expressed. This indicates that rescue of FPR-mediated apoptosis by arrestin
mutants is not due to effects on FPR internalization. In addition, internalization of
the ∆LIELD and F391A mutants is consistent with our previous studies showing
that FPR internalization is independent of clathrin (Gilbert et al., 2001) and,
similar to other GPCRs whose internalization is arrestin-independent (van
Koppen and Jakobs, 2004), is also independent of AP-2.

2.3.4 Arrestin-2 mutants that fail to rescue FPR-mediated apoptosis
accumulate in recycling endosomes.
As we have previously observed in arrestin-deficient cells, FPR-mediated
apoptosis is associated with defective intracellular trafficking, raising the question
as to whether the arr2-F391A and arr2-4A mutants allow normal trafficking of the
FPR and to what extent they remain associated with the receptor as it traffics
intracellularly.

Although the 6A mutant contains F391 and the 8A mutant

contains residues that have also been shown to regulate interactions with AP-2
(Edeling et al., 2006; Schmid et al., 2006), these mutants rescue FPR-mediated
apoptosis. Therefore, we decided to focus our subsequent studies on mutants
that do not rescue FPR-mediated apoptosis, namely the F391A and 4A mutants.
Localization of the FPR (visualized using an Alexa633 labeled N-formyl-LeucylLeucyl-Phenylalanyl-Leucyl-Tyrosinyl-Lysine ligand (633-6pep)) and arrestin-2
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mutants (tagged with monomeric red fluorescent protein, mRFP1 (Campbell et
al., 2002)) was determined using confocal fluorescence microscopy. Recycling
endosomes were visualized using a GFP fusion of Rab11. In unstimulated cells,
the Rab11 compartment is located in the perinuclear region and arrestin-2 (either
wild type or mutant) is dispersed throughout the cytoplasm. This is consistent for
all arrestin-2 mutants (unpublished data). Activation of the FPR with fluorescent
ligand (633-6pep) in the absence of arrestin-2 (empty mRFP1 vector-transfected)
resulted in accumulation of the FPR in recycling endosomes (Figure 2.5).
Expression of wild type arrestin-2, while also leading to localization of the FPR in
perinuclear recycling endosomes, resulted in a greater proportion of cytosolic
vesicles outside the recycling endosome containing FPR and arrestin, consistent
with normal trafficking and recycling of the FPR (Vines et al., 2003).
Cytosolic complexes of FPR-633-6pep and arrestin-2 are believed to
represent both internalized afferent endosomes as well as recycling efferent
vesicles based on two independent results. First, following a 10 min stimulation
of arrestin-deficient cells with 633-6pep, followed by 50 min chase without ligand,
the FPR is not seen in cytosolic vesicles, as it is in the presence of arrestins
(unpublished data). The presence of the FPR in vesicles after 50 min of agonist
depletion suggests that the vesicle-localized receptor represents recycling
receptor, since no such vesicles are seen in the arrestin-deficient cells. Second,
FPR internalization experiments performed with 10nM fMLF (the concentration of
633-6pep used in imaging experiments) in the presence of wild type arrestin-2,
reveal that the FPR achieves an equilibrium within 10 min wherein only
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approximately 25-30% of the total receptor is internalized (compared to 1 µM
fMLF, where 75-80% of the FPR is internalized). This equilibrium with less total
internalized receptor suggests that robust recycling is taking place under these
conditions.
Localization results for the mutant arrestins paralleled their apoptotic
phenotype. Expression of both the arr2-F391A and -4A mutants (which did not
rescue FPR-mediated apoptosis) resulted in accumulation of the FPR with
associated mutant arrestin in recycling endosomes. All other mutants (which did
rescue

the

apoptotic

phenotype)

produced

FPR

trafficking

indistinguishable from wild type arrestin-2 (Figure 2.5 and Fig 2.12).

patterns
These

results provide additional support for the correlation between FPR trafficking
defects and the initiation of FPR-mediated apoptosis observed in the complete
absence of arrestins as well as in the presence of the arr2-F391A and -4A
mutants.

2.3.5 Arrestin-2 mutants that prevent normal FPR trafficking exhibit altered
associations with AP-2.
Both the arr2-F391A and -4A mutants fail to rescue FPR-mediated
apoptosis and also demonstrate trafficking defects exemplified by accumulation
in perinuclear recycling endosomes.

The region of arrestin-2 encompassing

amino acids 391-400 has previously been associated with altered binding to AP-2
(Kim and Benovic, 2002; Milano et al., 2002).

The F391A mutant exhibits

decreased binding to AP-2, resulting in inhibition of β2-AR internalization. While
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the 4A mutant has not previously been described, three of the amino acids within
this mutant (K397, M399 and K400) have been individually assessed and shown
to exhibit decreased binding to AP-2 as well as decreased β2-AR internalization
similar to the F391A mutant (Kim and Benovic, 2002). To better understand the
relationship between AP-2 association and FPR trafficking, we used confocal
fluorescence microscopy to track the association of AP-2 with the FPR-arrestin
complex. Although previous studies of other GPCRs have examined arrestin2/AP-2 dynamics at early time points upon receptor internalization (Fessart et al.,
2005), we observed trafficking defects most clearly following one hour of receptor
stimulation. Therefore, we used a time course that examines FPR trafficking at
both short and long stimulation times.
To assess the interaction between AP-2 and the FPR-arrestin-2 complex,
we examined the subcellular localization of the GFP-fused α-subunit of AP-2, in
the context of internalized FPR (by tracking the activated 633-6pep-FPR
complex) and arrestin (by tracking RFP-fused arrestins) using confocal
fluorescence microscopy.

In unstimulated cells, all arrestins (wild type and

mutants) show a cytosolic distribution consistent with a lack of GPCR stimulation.
AP-2 is distributed throughout the cytoplasm as well as in puncta at the plasma
membrane. In the arr2-/-/3-/- FPR cells, following 60 minutes of stimulation with
633-6pep in the absence of arrestins, the FPR accumulates in a perinuclear
region (Figure 2.6) identified as the Rab11 recycling endosome (cf. Figure 2.5).
This observation and the lack of AP-2 association with the FPR in cytosolic
endosomes at 15 and 30 minutes in the absence of arrestins (Figure 2.13) are
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consistent with a requirement for arrestin-2 in the recruitment of AP-2. Upon
expression of wild type arrestin-2 in the arr2-/-/3-/- FPR cells, ligand stimulation
results in the accumulation of AP-2 with the 633-6pep-FPR/arrestin-2 complex in
the perinuclear region at 60 minutes.

However, AP-2 is not observed to

associate with cytosolic endosomes containing FPR-arrestin-2 complexes,
suggesting that AP-2 is not associated with the complex after exiting the
recycling endosome. At 15 minutes, almost no AP-2 was seen associated with
FPR-arrestin-2 complexes in recycling endosomes. It is not until 30 minutes that
significant levels of AP-2 are concentrated with the FPR and wild type arrestin-2
in recycling endosomes. We interpret these results to suggest that AP-2 does
not associate with FPR-arrestin-2 complexes prior to internalization.
Expression of the F391A and 4A arrestin mutants yield substantially
different results with respect to AP-2 association. In the presence of the arr2F391A mutant, AP-2 showed no association with the 633-6pep-FPR/arr2-F391A
complex at any of the time points (Figure 2.6 and Figure 2.13). This is consistent
with published reports that demonstrate decreased AP-2 binding to arr2-F391A
(Kim and Benovic, 2002). However, while we hypothesized that the same would
be true of the arr2-4A mutant, this was not the case. Following 60 minutes
stimulation, AP-2 showed strong colocalization with the 633-6pep-FPR/arr2-4A
complex, as strong as or stronger than that observed with wild type arrestin-2. A
similar association of AP-2 with the 633-6pep-FPR/arr2-4A complex was also
observed following 15 and 30 minutes stimulation. Our results suggest that the
arr2-4A mutant, in contrast to the arr2-F391A mutant, is capable of binding AP-2.
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The major difference between wild type arrestin-2 and the 4A mutant in this
assay is that there is little, if any, cytosolic 633-6pep-FPR/arr2-4A complex
(particularly at 60 min) suggesting an accumulation of complex in recycling
endosomes.
To determine the rate of association of AP-2 with FPR/arrestins, we
measured AP-2 colocalization with FPR/arrestin-2 complexes over time by
visually scoring the fraction of cells in which AP-2 was colocalized with
FPR/arrestin-2 perinuclear complexes (Figure 2.14). Results are normalized to
the response for wild type arrestin-2 at 60 minutes. At 15 minutes, 20-30% of
cells show AP-2 to be clustered with arrestin when either wild type arrestin-2 or
arr2-4A is expressed. The percentage of cells showing colocalization increased
at the 30 and 60 minute time points for both wild type arrestin-2 (~35 and ~80%,
respectively) and arr2-4A (~60 and ~95%, respectively).

The arr-2-F391A

mutant however showed essentially no AP-2 localization at any of the time points
assayed.
To confirm the above results and validate our use of a GFP-tagged αsubunit of AP-2, we examined U937 cells that stably express the FPR (U937
FPR) and both endogenous arrestins. U937 cells are a promonocytic cell line
used extensively as a model for FPR function (Browning et al., 1997; Hsu et al.,
1997). Confocal immunofluorescence microscopy of U937 FPR cells transiently
expressing Rab11-GFP and stained with antibodies against endogenous AP-2
confirms our results regarding the subcellular localization of AP-2 (Figure 2.15A).
In unstimulated cells, Rab11-GFP is localized to the perinuclear region while AP38

2 shows puncta at the cell membrane with limited cytosolic staining.

Upon

stimulation of the FPR with Alexa 546-6pep (546-6pep) for 30 min, ligand-FPR
complexes colocalize with endogenous AP-2 in the Rab11 endosome.

In

addition, ligand-receptor complexes exist outside the perinuclear region, but with
little or no AP-2 staining, consistent with the idea that AP-2 only associates
significantly with the FPR at recycling endosomes. Alternatively, these vesicles
may represent efferent recycling endosomes (see below).
While colocalization of scaffolded proteins helps to define aspects of
receptor trafficking and provides sub-micron resolution, it cannot directly
measure protein complex formation. To extend our microscopy results (Figure
2.6), we immunoprecipitated FLAG-tagged arrestins and assayed AP-2 complex
binding over a time course of FPR-activation (Figure 2.7A). We added additional
shorter time points as compared microscopy assays to determine whether
FPR/arrestin/AP-2 complexes form prior to their detection by colocalization in
punctate structures.

Western blotting with antibodies directed against the β-

subunit of AP-2 (the subunit that directly binds wild type arrestin-2 (Fessart et al.,
2005)) did not detect any adaptin following immunoprecipitation with anti-FLAG
antibodies using arrestin-deficient cell lysates. Upon expression of FLAG-tagged
wild type arrestin-2 in arrestin-deficient cells and immunoprecipitation of arrestin2, β-adaptin was detected in the immunoprecipitate as early as 5 minutes
(quantitated in Figure 2.7B), but not in unstimulated cells. Although there was
virtually no detectable binding of AP-2 to the F391A mutant, particularly at the
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later time points, AP-2 bound to the 4A mutant to a much greater extent than wild
type arrestin-2 (~6-fold increase).

2.3.6 FPR displays differential trafficking with AP-1 complexes in the
presence of arrestins.
AP-1 has been localized to the TGN and perinuclear recycling endosome
of cells and is required for trafficking of proteins from these compartments to the
plasma membrane (Miedel et al., 2006; Pagano et al., 2004). In addition, the
beta-subunit of AP-1 (which in AP-2 directly binds arrestin-2) shows significant
overall homology to the beta-subunit of AP-2. In addition, amino acids shown to
be necessary for arrestin-2 binding to β2-adaptin (E849, Y888 and E902)
(Laporte et al., 2002) are absolutely conserved in β1-adaptin (Lundmark and
Carlsson, 2002). To determine whether AP-1 might also play a role in FPR
trafficking, we examined the localization of the FPR, arrestins and AP-1 using
confocal fluorescence microscopy.

In unstimulated cells, AP-1 was localized

primarily in a perinuclear region, but was also present in the cytoplasm. When
the FPR was stimulated in the absence of arrestins, receptor accumulated in the
perinuclear recycling endosome (see Figure 2.5) and it colocalized extensively
with AP-1, with little or no receptor observed outside this compartment (Figure
2.8A).

Upon stimulation of cells expressing wild type arrestin-2, the FPR-

arrestin-2 complexes were extensively localized with AP-1 in the perinuclear
region. However, arrestin was also observed outside this region in cytoplasmic
vesicles in association with the FPR and AP-1.
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This suggests that upon

internalization, the FPR traffics to recycling endosomes where it associates with
AP-1, which is likely involved in escorting the receptor back to the cell surface.
The fact that arrestin appears to mediate these late trafficking events indicates a
role for arrestin in receptor trafficking at a much later stage than previously
thought. In contrast to wild type arrestin-2, the F391A and 4A mutants both
accumulated with the FPR in the AP-1-positive endosome in the perinuclear
region with no receptor, arrestin or AP-1 observed outside this cellular
compartment, consistent with the lack of recycling.

To further assess AP-1

trafficking with FPR/arrestin-2 complexes, we quantitated the number of cells that
show AP-1 puncta outside of the perinuclear region (Figure 2.8B).

Results

demonstrate that only when wild type arrestin-2 is present is AP-1 observed on
vesicles outside the perinuclear region following FPR activation. Finally, pulsechase experiments (10 min pulse with 633-6pep, 50 min chase) using arr2-/-/3-/FPR cells transiently transfected with γ-GFP show that AP-1 is colocalized with
633-6pep-FPR-wild type arrestin-2 in cytoplasmic vesicles following the 50 min
chase, but not in early endosomes immediately following internalization (10 min
pulse with no chase, unpublished data).
In order to confirm that the GFP-fused γ-subunit of AP-1 accurately
reflects endogenous AP-1 trafficking, we used confocal immunofluorescence
microscopy in U937 FPR cells transiently transfected with Rab11-GFP (Figure
2.15B). In unstimulated cells, AP-1 is predominantly colocalized with perinuclear
Rab11 with minimal cytosolic staining. Upon stimulation of the FPR with 5466pep, ligand-receptor complexes colocalize with Rab11 and AP-1 in the
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perinuclear region. In addition, ligand-receptor complexes found in endosomes
outside the perinuclear region also colocalize significantly with AP-1 consistent
with efferent trafficking of the FPR.

2.3.7 AP-1 binds arrestin in an FPR activation-dependent manner.
Based on the colocalization of the FPR, arrestin and AP-1 upon receptor
activation, we sought to determine whether arrestin also forms a complex with
AP-1. Arr2-WT-FLAG was transiently transfected into arr2-/-/3-/- FPR cells, and
activated prior to immunoprecipitation with anti-FLAG antibodies (Figure 2.8C).
AP-1 complex was detected in the immunoprecipitates by blotting for the γsubunit of AP-1. In the absence of arrestins, AP-1 was not detected in anti-FLAG
immunoprecipitates. However, in the presence of arr2-WT-FLAG, the γ-subunit
of AP-1 was detected in the anti-FLAG immunoprecipitates in a stimulationdependent manner, suggesting an association between the FPR-arrestin
complex and AP-1, particularly at times consistent with receptor recycling.

2.3.8 Arrestin mutants and AP-2 regulate recycling of the FPR.
Previous reports have demonstrated that recycling of the FPR is impaired
in the absence of arrestins and that this phenotype is rescued by reconstitution
with wild type arrestin-2 (Vines et al., 2003). Similar to our previous results, in the
current experiments, arr2-/-/3-/- FPR cells recycled ~6% of internalized FPR
whereas arr2+/+/3+/+ FPR cells recycled ~30% of internalized receptor with similar
initial levels of internalization (unpublished data). Arr2-/-/3-/- FPR cells transfected
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with EGFP alone do not recycle significant amounts of internalized FPR whereas
reconstitution with wild type arrestin-2 significantly increases the amount of FPR
recycled to ~15% (unpublished data). Expression of either the F391A or 4A
mutants yielded no significant recycling of FPR (~5% for the 4A mutant and no
recycling for the F391A mutant, unpublished data). These results confirm that
the accumulation of the FPR in recycling endosomes in the presence of the
F391A or 4A mutants corresponds to a lack of recycling as a result of a block in
efferent trafficking from Rab11-containing recycling endosomes.
In order to determine explicitly whether AP-2 and AP-1 regulate FPR
recycling, we used siRNAs to knockdown the µ1A and µ2 subunits of AP-1 and
AP-2, respectively in U937 FPR cells (Figure 2.9A). Knockdown of µ1A and µ2
subunit expression was >90% in both cases (unpublished data). In addition,
expression of the β-subunit of AP-2 and γ-subunit of AP-1 was decreased as
well, but not to the same extent (>70% and >50% respectively, unpublished
data). Although the rate of FPR internalization was not affected by knockdown of
either AP-2 or AP-1 (control, 1.4+/-0.2 min; AP-1, 1.5+/-0.15 min; AP-2, 1.6+/0.18 min), the extent of FPR internalization was modestly reduced upon AP-2
knockdown (control, 75+/-2%; AP-1, 82+/-3%; AP-2, 57+/-5%). FPR recycling
was measured relative to the amount of internalization for each condition
normalized to the extent of recycling in cells electroporated with control siRNA.
Whereas knockdown of AP-2 produced a significant decrease of about 40% in
FPR recycling (p<0.05), knockdown of AP-1 produced no effect (Figure 2.9B).
Finally, U937 FPR cells treated with siRNAs were stimulated with 546-6pep for
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30min and imaged by confocal fluorescence microscopy.

Ligand-receptor

complexes were observed in the perinuclear region under all conditions, but
when AP-2 levels were reduced, liganded FPR exhibited increased juxtanuclear
accumulation with reduced peripheral vesicles being observed (unpublished
data).

These results confirm an essential role for AP-2 in the recycling of the

FPR.

2.3.9 Endogenous AP-2 and AP-1 traffic differentially with the FPR.
In order to determine whether AP-2 and AP-1 specifically colocalize with
each other in response to FPR stimulation and trafficking, U937 FPR cells were
transiently transfected with GFP subunits of either AP-2 or AP-1 and stained for
the complimentary adaptor protein with antibodies to AP-2 and AP-1 subunits
(Figure 2.9C). In unstimulated cells, GFP-fused AP-1 and antibody staining of
endogenous AP-1 show a perinuclear region and some cytosolic distribution.
Similarly, GFP-fused AP-2 and staining of endogenous AP-2 both demonstrate a
punctate localization at the plasma membrane with additional diffuse cytosolic
expression. Upon stimulation of the FPR with 546-6pep for 30min, ligand-FPR
complexes are present in a perinuclear location colocalized with both AP-2 and
AP-1. Under these conditions, AP-2 is only seen with the FPR in the perinuclear
location and AP-1 is seen in the perinuclear location as well as in cytosolic
endosomes consistent with normal efferent FPR trafficking. These results not
only validate the use of GFP-fused AP constructs but also confirm and extend
the conclusions drawn from studies in MEF cells.
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2.4

DISCUSSION
Receptor trafficking is important to proper receptor and therefore cell

function. We have previously suggested a link between FPR-mediated apoptosis
and altered FPR trafficking in the absence of arrestins (Revankar et al., 2004;
Vines et al., 2003). In this report, we demonstrate that arrestin mutants that do
not rescue FPR-mediated apoptosis accumulate in the Rab11, perinuclear
recycling compartment.

Furthermore, accumulation of receptor in this

compartment was shown to be due to impaired recycling of internalized FPR in
the presence of F391A and 4A mutants, resulting from altered AP-2 binding to
arrestin-2.

Associations between arrestin and AP-2 and AP-1 were also

demonstrated by confocal microscopy and co-immunoprecipitations.

siRNA-

mediated knockdown of AP-2 confirmed the necessity of this interaction in FPR
recycling, although an absolute requirement for an interaction with AP-1 in FPR
recycling could not be demonstrated. As signaling inhibitors have been shown to
inhibit FPR-mediated apoptosis, our results suggest that inhibition of proper FPR
trafficking also alters proper spatial control of FPR signaling complexes leading to
the initiation of apoptosis within the cell. This is supported by results that show
spatial control of GPCRs can induce or limit their potential to create signaling
complexes and initiate cellular signaling pathways (Daaka et al., 1998).
While the internalization of numerous GPCRs require arrestin, AP-2 and
clathrin, the FPR was one of the first GPCRs suggested to internalize through
arrestin- and clathrin-independent mechanisms (Bennett et al., 2001; Gilbert et
al., 2001; Maestes et al., 1999).

Arrestin independence was ultimately
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definitively demonstrated using arrestin-deficient mouse embryonic fibroblasts, in
which the stably expressed FPR exhibited normal internalization (Vines et al.,
2003).

Consistent with this observation is the fact that none of the arrestin

mutants used in this study defective in AP-2/clathrin binding (F391A and ∆LIELD,
respectively) or arrestin dephosphorylation (S412D) inhibited FPR internalization.
These results also indicate that a lack of receptor internalization was not
responsible for the observed rescue of apoptosis by certain arrestin mutants
(∆LIELD and S412D). Overall, these results support the conclusion that FPR
internalization is independent of AP-2, clathrin and the phosphorylation state of
arrestin.
Both arrestin mutants used in this study that did not rescue FPR-mediated
apoptosis did inhibit FPR trafficking by preventing FPR recycling as a result of
altered interactions with AP-2. The F391A arrestin mutant was previously shown
to exhibit decreased binding to the β-subunit of AP-2 through in vitro binding
assays while its overexpression in cells inhibited internalization of the β2-AR
(Milano et al., 2002). While the 4A mutant has not been previously described,
the mutation and characterization of individual amino acids (K397, M399 and
K400) have been described (Kim and Benovic, 2002). These individual mutants
showed similar binding properties with the β-subunit of AP-2 and produced
similar effects on β2-AR internalization as the F391A mutant. What we found
most surprising was the differential interaction these arrestin mutants displayed
with the AP-2 complex. While the F391A mutant did not significantly colocalize
or co-immunoprecipitate with AP-2 at any time point or at any location within the
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cell, the 4A mutant strongly colocalized with AP-2 upon FPR activation. In fact,
co-immunoprecipitation assays demonstrated increased binding of AP-2 to the
4A mutant compared to wild type arrestin-2. The reason for increased AP-2
binding to an arrestin mutant whose component mutations show decreased
binding is unclear, but may be due to conformational changes within the protein
that alter the binding properties of this specific motif or other secondary sites. It
is intriguing that in addition to decreased binding of AP-2 to arrestin-2, increased
association also inhibits the proper trafficking of the FPR.
A recent report (Schmid et al., 2006) suggests that the region of arrestin
between amino acids 383-402 forms an α-helix as it binds the β-subunit of AP-2.
The 4A mutant may form a more stable α-helix that increases binding to AP-2
through the remaining AP-2 interacting residues such as F391, R393 and R395
or alternatively it may exist in a constitutively active state as previously described
for the arrestin-2 3A mutant (I386A/V387A/F388A), which dislodges the tail of
arrestin from the body of the protein (Gurevich and Gurevich, 2004). Another
constitutively active mutant of arrestin (R169E in the polar core of the protein)
has also been shown to exhibit increased binding to AP-2 (Kim and Benovic,
2002). Surprisingly, the 6A mutant, which rescued FPR-mediated apoptosis and
bound to activated FPR, lacked many of the residues that have been
demonstrated to be involved in the association with AP-2, suggesting the 6A
mutant may bind AP-2 at alternate or secondary sites. Similar to our 4A mutant,
an AP-2 mutant R879A shows significantly enhanced (10-fold) binding to
arrestin-2 (Schmid et al., 2006), suggesting that this interaction can be both
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positively and negatively modulated by mutations in both arrestin and AP-2. The
inhibitory effect of increased AP-2 binding by the 4A mutant suggests that
appropriate cycling of AP-2 with arrestin (association followed by dissociation) is
required for the exit of the FPR from recycling endosomes.

This idea is

supported by recent evidence demonstrating Src activity as a necessary
component for AP-2/arrestin dissociation and internalization of the β2-AR
(Fessart et al., 2005). When Src activity was inhibited, AP-2 remained bound to
arrestin and β2-AR internalization was decreased. While the regulation of β2-AR
trafficking by AP-2 clearly occurs at the plasma membrane, arrestin’s role in FPR
trafficking appears to lie specifically with its recycling and not its internalization
leaving AP-2’s role in GPCR trafficking an intriguing phenomenon in GPCR
function. Other GPCRs likely colocalize with AP-2 in the perinuclear region as
well.

In a recent report (Mundell et al., 2006), the authors found that two

purinergic receptors, P2Y1 and P2Y12, colocalized with AP-2 in perinuclear
“endocytic compartments”, though the identity of this compartment was not
established.
A significant remaining question is: What regulates the location at which
AP-2 mediates its effects on GPCR-arrestin complexes?

We have recently

shown that the phosphorylation pattern of the FPR is highly complex with respect
to its regulation of arrestin binding, internalization and desensitization (Potter et
al., 2006).

Although the presence of a single phosphorylation site can be

sufficient to initiate internalization and arrestin binding, the presence of additional
sites can inhibit arrestin binding without affecting receptor internalization.
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Furthermore, work by our lab has suggested that the pattern of phosphorylation
sites within the FPR carboxy terminus regulates arrestin affinity for the FPR, its
ability to induce changes in ligand affinity, as well as the intracellular trafficking
pattern of internalized receptors (Key et al., 2001; Key et al., 2003; Key et al.,
2005; Xue et al., 2004). The stability/affinity of the receptor-arrestin interactions
also regulates the trafficking of the β2-AR and vasopressin V2 receptors. These
effects are likely a result of carboxy terminus phosphorylation patterns, as
exchanging the carboxy terminus of the β2-AR for that of the vasopressin V2
receptor produced a trafficking pattern typical of the vasopressin V2 receptor
(Oakley et al., 1999; Oakley et al., 2000). A similar conclusion regarding the
complexity of receptor phosphorylation has recently been made based on
functional studies of the β2-AR following manipulations of GRK and arrestin
expression (Kim et al., 2005; Ren et al., 2005).

The results suggested that

GPCR phosphorylation patterns resulting from the activity of GRK4/5 but not
GRK2/3 produce arrestin-mediated signaling functions through ERK1/2.

We

therefore speculate that the initial phosphorylation of the FPR upon ligand
binding may be sufficient to initiate internalization but insufficient to promote
arrestin binding.

Only upon additional phosphorylation, perhaps following

internalization, is the receptor then competent for arrestin binding. Furthermore,
it is possible that additional receptor or arrestin phosphorylation/modification may
be required to permit the binding of AP-2 to FPR-arrestin complexes within
endosomes.
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Although AP-1 is predominantly known for mediating vesicle traffic from
the Golgi compartment to the plasma membrane, it has also been shown to be
involved in the formation of recycling vesicles (Deneka et al., 2003; Popa et al.,
2005). To our knowledge, our report is the first to suggest a role for AP-1 in the
post-endocytic processing of GPCRs. Colocalization studies with the FPR and
arrestins demonstrate that upon FPR stimulation, receptor and arrestins
colocalize with AP-1 in a perinuclear region.

However, while the FPR and

arrestins-F391A/4A remain with AP-1 in this region, in the presence of wild type
arrestin-2, vesicles containing FPR, arrestin and AP-1 are observed outside the
perinuclear region. Although AP-1 associates with arrestin in an FPR activationdependent manner, siRNA studies do not show an effect on FPR recycling. In a
recent review (Robinson, 2004), AP-4 was described as having possible
additional functions, besides being localized in the Golgi and trafficking cargo to
the cell surface. It may be that AP-4, or another trafficking protein, is capable of
serving a redundant function to AP-1 when its levels are decreased.
Based on the results of this study, we propose a new model of FPR
internalization and recycling (Figure 2.10). In this model, following ligand binding
the FPR internalizes in an arrestin-independent manner. After, or perhaps during
internalization, the FPR binds to arrestin, resulting in the presence of
FPR/arrestin complexes in early endosomes. At some point during its trafficking
to the Rab11, perinuclear recycling endosome (or after its arrival at this location)
the FPR-arrestin complex recruits AP-2.

Within or as it exits the recycling

compartment, the FPR/arrestin complex releases AP-2.
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AP-1 mediated

trafficking subsequently facilitates exit of the FPR/arrestin complex from recycling
endosomes and their return to the cell surface. Along the path to the cell surface
the complex dissociates and the FPR is dephosphorylated. Finally, the FPR
completes its return to the cell surface in a resensitized form ready to continue
signaling.
In this report, we have described a novel mechanism for GPCR postendocytic trafficking and recycling. This is the first report that begins to reveal
the protein-protein interactions necessary for the recycling of certain GPCRs,
revealing a definitive role for arrestin in the late stages of GPCR trafficking as
compared to the β2-AR, where arrestins are involved in the earliest events of
GPCR trafficking (McDonald and Lefkowitz, 2001). Furthermore, the fact that
FPR-mediated apoptosis occurs under conditions where arr2-F391A/-4A are
bound to the FPR demonstrates that the FPR-initiated apoptotic signaling is not
purely a result of receptor activation in the absence of arrestins and confirms that
receptor-arrestin accumulation in recycling endosomes results in aberrant
signaling that leads to apoptosis. With this report of novel roles for arrestins and
adaptor proteins in the trafficking and signaling of GPCRs, new avenues for the
targeting of GPCR function are presented that may lead to therapeutic
interventions for disease processes.
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2.5

MATERIALS AND METHODS

2.5.1 Reagents, Plasmids and Mutagenesis. All reagents are from Sigma
unless otherwise noted.

With the exception of the arr2-F391A and -∆LIELD

mutants, regions of arrestin-2 were mutated by site-directed mutagenesis and
cloned into EGFP-N1 vector or mRFP1 vector using standard subcloning
procedures and HindIII/ApaI restriction sites.

Arr2-F391A and -∆LIELD

constructs were a gift from Jeffrey Benovic. These constructs were amplified
using PCR with primers that created HindIII/ApaI restriction sites and subcloned
as describe above. Arr2-WT-FLAG was created by cutting Arr2-WT-GFP at the
ApaI/NotI restriction sites to remove GFP and inserting a linker that contained the
FLAG sequence. Arr2-F391A- and Arr2-4A-FLAG were constructed by digesting
with HindIII/ApaI sites and subcloning the ~1300bp fragment into the HindIII/ApaI
restriction sites of Arr2-WT-FLAG.

All mutants were confirmed by DNA

sequencing. Rab11-GFP was a gift from Angela Wandinger-Ness. GFP-fused
α-subunit of AP-2 and GFP-fused γ-subunit of AP-1 (Wu et al., 2003) were gifts
from Lois Greene.
2.5.2. Cell Culture and Transfection.

Arr2-/-/3-/- FPR cells were grown in

DMEM with 10% fetal bovine serum, 100 units/mL penicillin and 100units/mL
streptomycin at 37°C and 5% CO2. U937 FPR cells were grown in RPMI with
10% fetal bovine serum, 100 units/mL penicillin and 100units/mL streptomycin at
37°C and 5% CO2. Transient transfections of mouse embryonic fibroblasts were
performed with Lipofectamine 2000 according to manufacturer’s instructions.
siRNA transfection of U937 FPR cells was performed using siPORT
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Electroporation Buffer (Ambion) with a Genepulser Xcell (Bio Rad) according to
manufacturer instructions. Cells were transfected with 20μg of siRNA twice at 72
hour intervals. Cells were assayed 72 hours after the second transfection. Cell
survival was measured using Trypan Blue and was >95% for all transfections.
siRNAs used for depletion of µ1A (AP-1) and µ2 (AP-2) were as previously
described (Janvier and Bonifacino, 2005). mRNA gene target sequences for
siRNA design were as follows: µ1A—GGCAUCAAGUAUCGGAAGA; µ2—
GUGGAUGCCUUUCGGGUCA. A nonfunctional siRNA (Ambion) was used as a
control.
2.5.3 Cell Rounding.

Arr2-/-/3-/- FPR cells transiently transfected with GFP-

fused arrestins were plated on 12mm-glass coverslips, incubated overnight and
serum-starved for 30 minutes. Cells were incubated in SFM or were stimulated
with 10nM fMLF in SFM 5 hours at 37°C. Cells were washed twice with PBS,
fixed with 2% paraformaldehyde and mounted using Vectashield. Slides were
viewed by phase-contrast microscopy and random fields were evaluated (at least
five) until 100-300 GFP-expressing cells were assayed. GFP-expressing cells
were counted “positive” for cell death if they rounded or if they were spherical
refractile cells with no extensions.

Data are expressed as a percentage of

rounded/GFP-expressing cells.
2.5.4. Apoptosis. Arr2-/-/3-/- FPR cells transiently transfected with GFP-fused
arrestins were plated on 12mm-glass coverslips, incubated overnight and serumstarved for 30 minutes. Cells were incubated with SFM or were stimulated with
10nM fMLF in SFM for 5 hours at 37°C. Cells were stained with 100ng/mL
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propidium iodide in SFM at room temperature for 5-10 minutes, washed twice
with PBS, fixed with 2% paraformaldehyde and mounted using Vectashield.
Slides were viewed by fluorescence microscopy and random fields were
evaluated (at least five) until 100-300 GFP-expressing cells were assayed. GFPexpressing cells were counted “positive” for cell death if they were stained with
propidium iodide.

Data are expressed as a percentage of PI-positive/GFP-

expressing cells.
2.5.5. FPR Internalization.

Arr2-/-/3-/- FPR cells transiently transfected with

GFP-fused arrestins were harvested by trypsinization.

U937 FPR cells were

electroporated with siRNAs and harvested by centrifugation.

Cells were

resuspended in SFM and stimulated for 2, 5, 10, 20 and 30 minutes with 1µM
fMLF. Cells were then washed extensively with cold SFM to remove excess
unlabelled ligand. Remaining receptors on the cell surface were labeled with
10nM 633-6pep. Cells were then assayed by flow cytometry using a BectonDickinson FACSCalibur. Cells (100,000) were gated for live cells using forward
and side scatter parameters. GFP-fused arrestin mutant expressing cells were
subsequently gated using FL-1 and the mean channel fluorescence (MCF) was
determined in FL-4 to monitor cell surface expression of the FPR. Non-specific
binding was determined by labeling arr2-/-/3-/- cells not expressing the FPR with
633-6pep and assaying as described.

Non-specific binding was subtracted

before further calculations. MCF from unstimulated cells represented 100% FPR
cell surface expression.

Cell surface expression from stimulated cells was

calculated by dividing the MCF following treatment by the MCF from unstimulated
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cells. Internalization data were then plotted using GraphPad Prism to calculate
maximum internalization extents using a singe exponential decay.

Statistical

analysis was performed using Student’s t-test.
2.5.6. Confocal Fluorescence Microscopy. Arr2-/-/3-/- FPR cells or U937 FPR
cells were transiently transfected with RFP-fused arrestins and GFP-fused
Rab11, α-subunit of AP-2 or γ-subunit of AP-1. Arr2-/-/3-/- FPR cells were plated
on 25mm-glass coverslips and grown overnight. U937 FPR cells were harvested
by centrifugation. Cells were serum-starved for 30 minutes and stimulated with
10 nM 633- or 546-6pep in SFM for indicated time at 37°C.

Coverslips or

harvested cells were rinsed with PBS, fixed with 2% paraformaldehyde at room
temperature and mounted with Vectashield.

For experiments using antibody

staining, after fixation cells were incubated in 0.02% Saponin/3% BSA for 15-20
minutes at room temperature.

Cells were washed and incubated in 1:100

primary antibody (100/3 for γ1-adaptin antibody or AP-6 for α-adaptin (Affinity
Bioreagents)) in 3% NGS for 30 minutes at room temperature.

After further

washing, cells were incubated in 1:200 secondary antibody (Cy5-conjugated
Donkey Anti-Mouse (Jackson Immunoresearch)) in 3% NGS for 30 minutes at
room temperature. Cells were then washed and mounted using Vectashield.
Fluorescence images were acquired using a Zeiss LSM 510 inverted laser
scanning microscope equipped with He-Ne and Kr-AR lasers. To assess the
extent of colocalization, cells with perinuclear arrestin clusters were viewed and
scored for the presence of any corresponding AP-2 clusters.
expressed

as

mean

+/-

SEM

AP-2
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clusters/arrestin

Data were

clusters

in

>25

cells/experiment and were normalized to the wild type arrestin response at 60
minutes.
2.5.7. Cell Lysis and Immunoprecipitation.

Arr2-/-/3-/- FPR cells transiently

transfected with FLAG-tagged arrestins were grown to confluence. Cells were
serum-starved for 30 min and stimulated for the designated times with 10nM
fMLF in SFM at 37°C. Media was removed and 1mL of cold co-IP lysis buffer
(1% v/v TX-100, 150mM NaCl, 10mM Tris-HCl pH 7.4 supplemented with
protease inhibitor cocktail (Calbiochem)) was added immediately. Lysates were
collected, incubated on ice for 30 min, and centrifuged at maximum speed for 30
min at 4°C.

An aliquot from each tube was set aside for determining pre-

immunoprecipitation

levels

of

proteins

by

Western

blot.

For

immunoprecipitations, 25µL of protein A Sepharose (Pierce) was washed three
times with co-IP lysis buffer. Beads were rotated for at least one hour at 4°C in
250µL of co-IP lysis buffer with 1:1000 M2 Anti-FLAG antibody. Beads were
washed with co-IP lysis buffer and lysates were added and rotated overnight at
4°C. The following day, beads were washed again with co-IP lysis buffer, 40µL
of 2X Sample Buffer was added and immunoprecipitated proteins released by
boiling for 5 minutes.
2.5.8. Western Blotting.

Lysates or immunoprecipitates were resolved with

SDS-PAGE. Proteins were transferred to PVDF membranes and blocked for 1
hour with 5% dry milk in TBS-T. Blotting was carried out using 1:1000 dilutions
of biotinylated M2 mouse anti-FLAG antibody, M2 mouse Anti-FLAG, mouse antiβ-adaptin antibody (BD Biosciences), mouse 100/3 to γ1-adaptin antibody, rabbit
56

RY/1 to μ1A (gift from L. Traub), rabbit R11-29 to μ2 ((Aguilar et al., 1997), gift
from J. Bonifacino) and 1:4000 mouse anti-GAPDH antibody (Chemicon) in 5%
dry milk in TBS-T overnight at 4°C.

Blots were washed with TBS-T and

incubated with 1:2500 HRP-streptavidin (in 5% BSA in TBS-T), 1:2500 HRP
rabbit anti-mouse antibody or 1:2500 HRP goat anti-rabbit antibody (in 5% Dry
Milk in TBS-T) at room temperature for 1 or 3 hours, respectively. Bands were
visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Densitometry was performed using Quantity One (BioRad) and ratios expressed
as mean ratio +/- SEM adaptin/arrestin immunoprecipitated and normalized to
zero time points for each vector expressed.
2.5.9. FPR Recycling. Arr2-/-/3-/- FPR cells transiently transfected with GFPfused arrestins or U937 FPR cells transfected with siRNA were harvested and
resuspended in SFM. An aliquot was removed to measure total cell surface
receptor. The remaining cells were stimulated with 1µM fMLF in SFM at 37°C for
1 hour and were then washed extensively to remove excess unlabelled ligand.
Half the remaining cells were resuspended in pre-warmed SFM for 30 min at
37°C (20 min for U937 FPR cells) to allow the FPR to recycle. The other half
was kept on ice to measure post-internalization cell surface receptor levels. All
aliquots were then resuspended in SFM containing 10nM 633-6pep and assayed
by flow cytometry using a Becton-Dickinson FACSCalibur. For analysis, assayed
cells were gated for live cells using forward and side scatter parameters. These
cells were then gated using FL-1 for GFP-fused arrestin mutant expression and
the mean channel fluorescence was measured in FL-4 to monitor cell surface
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expression of the FPR. Non-specific binding was determined by labeling arrestin
knockout cell lines (or U937 cells lines) that did not express FPR and was
subtracted from all values. To account for differences in total recycling that could
be due to differences in the initial extent of internalization, the fraction of recycled
FPR (starting from the final internalization time point) was divided by the fraction
of internalized FPR. Data are expressed as a percentage of recycled receptor
/internalized receptor.
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2.7

ABBREVIATIONS

AP-1—adaptor protein-1 complex
AP-2—adaptor protein-2 complex
Arr2—arrestin-2
Arr2-/-/3-/- FPR—arrestin-2-/-/-3-/- knockout MEF cells stably expressing the FPR
fMLF—N-formyl-Methionyl-Leucyl-Phenylalanine
FPR—N-formyl peptide receptor
GPCR—G protein-coupled receptor
MEF—mouse embryonic fibroblast
PI—propidium iodide
SFM—serum-free medium (DMEM or RPMI)
6pep—N-formyl-Leucyl-Leucyl-Phenylalanyl-Leucyl-Tyrosinyl-Lysine
U937 FPR—U937 cells stably expressing the FPR
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2.8

FIGURE LEGENDS

2.8.1. Figure 2.1.

Structural regions of arrestin-2 do not rescue FPR-

mediated apoptosis. Arr2-/-/3-/- FPR cells were transiently transfected with wild
type or structural regions of arrestin-2 fused to GFP. Cells were stimulated for 5
hours in SFM with 10nM fMLF or vehicle at 37°C. GFP-expressing cells were
randomly viewed using phase-contrast microscopy and counted for normal
morphology or cell rounding. Only wild type arrestin-2 was capable of preventing
FPR-mediated apoptosis.

Data are expressed as mean +/- SEM rounded

cells/GFP-expressing cell from three independent experiments.

2.8.2. Figure 2.2. Sequence of arrestin-2 carboxy terminus and selected
mutants. Arrestin-2 mutants within the carboxy terminus were designed based
on previously described mutations or by changing regions of qualitatively similar
amino acids (e.g. groups of charged residues) to alanine. An additional mutant,
∆LIELD (located just before the site of truncation at amino acid 382), lacking the
clathrin-binding motif, was also used.

2.8.3. Figure 2.3.

Rescue of FPR-mediated apoptosis by arrestin-2

mutants. Arr2-/-/3-/- FPR cells transiently transfected with GFP-fused arrestin
mutants were assayed for apoptosis. Cells were stained with PI and 100-300
GFP-expressing cells were viewed and scored for the presence of PI staining.
Only in the absence of arrestin (EGFP vector only) or in the presence of arr2-(1382), arr2-4A and arr2-F391A did the cells continue to undergo FPR-mediated
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apoptosis. All other mutants prevented apoptosis like wild type arrestin-2. Data
expressed as mean ± SEM PI positive/GFP cell from three independent
experiments.

2.8.4. Figure 2.4.

Internalization of the FPR in presence of arrestin-2

mutants. Arr2-/-/3-/- FPR cells transiently transfected with GFP-fused arrestins
were stimulated with 1µM fMLF and aliquoted at multiple time points. Cells were
washed free of fMLF, labeled with 633-6pep and analyzed by flow cytometry for
residual cell surface receptor. Cells were gated for GFP expression (FL1) to
restrict the analysis to transfected cells. Data are expressed as the maximum
extent of internalization based on curve fitting using a single exponential decay.
Data are expressed as mean ± SEM from three independent experiments

2.8.5. Figure 2.5.

Arrestin-2 mutants incapable of rescuing apoptosis

accumulate in recycling endosomes.

Arr2-/-/3-/- FPR cells were transiently

transfected with GFP-fused Rab11 and RFP-fused arrestins (wild type, arr2-4A,
arr2-F391A and arr2-S412D) and plated on coverslips. Cells were stimulated
with the 633-6pep for 1 hour at 37°C and imaged by confocal fluorescence
microscopy using a 63X objective. In the absence of arrestin or the presence of
arr2-4A or arr2-F391A, the FPR-ligand complex accumulated extensively in the
Rab11 compartment. In cells expressing wild type arrestin-2 and arr2-S412D,
the receptor is also seen in cytoplasmic vesicles. Representative images are
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shown from three independent experiments.

Scale bars, 10µm. See Figure

2.12 for images of additional mutants.

2.8.6. Figure 2.6.

Arrestin-2 mutants differentially colocalize with AP-2.

Arr2-/-/3-/- FPR cells were transiently transfected with RFP-fused arrestins (wild
type, arr2-F391A and arr2-4A) and the GFP-fused α-subunit of AP-2. Cells were
subsequently stimulated with 633-6pep at 37°C for the indicated time and imaged
by confocal fluorescence microscopy with a 63X objective. In cells expressing
wild type arrestin-2 or arr2-4A, following 60 min stimulation, AP-2 is localized with
the FPR and arrestin in perinuclear endosomes.

On the contrary, in cells

expressing arr2-F391A, no AP-2 is associated with internalized receptor.
Representative images are shown from three independent experiments. Scale
bars, 10µm. See Figure 2.13 for images of additional time points.

2.8.7. Figure 2.7. Immunoprecipitation of AP-2 with arrestin-2 mutants. A)
Arr2-/-/3-/- FPR cells were transiently transfected with FLAG-tagged arrestins.
Cells were stimulated for the indicated times with 10nM fMLF and lysed. Lysates
were immunoprecipitated with anti-FLAG antibodies, resolved by SDS-PAGE and
blotted for FLAG-tagged arrestins and the β-adaptin subunit of AP-2.
Representative blots are shown. B) Quantitation of immunoprecipitated bands
by optometric density.

Data are expressed as mean +/- SEM ratio of β-

adaptin/arrestin intensity and normalized to respective zero time points. Data are
from three independent experiments.
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2.8.8. Figure 2.8. FPR-arrestin-2 trafficking and binding with AP-1. A) Arr2/-

/3-/- FPR cells were transiently transfected with RFP-fused arrestins (wild type,

arr2-F391A and arr2-4A) and the GFP-fused γ-subunit of AP-1. Cells were then
stimulated with the 10nM 633-6pep ligand, fixed and viewed by confocal
fluorescence microscopy.

In all cases, after 60min stimulation, FPR-arrestin

complexes were associated with AP-1. Note that only with the stimulated cells
expressing wild type arrestin-2 are cytoplasmic vesicles containing AP-1, FPR
and arrestin observed outside the recycling endosomes. Representative images
are shown from three independent experiments. Scale bars, 10µm. B) AP-1
differentially associates with cytosolic arrestin clusters. Association of AP-1 with
cytosolic arrestin-containing clusters was determined by viewing cells with
cytosolic arrestin clusters and scoring whether or not colocalized AP-1 clusters
were also present. Data are expressed as mean +/- SEM for >30 cells from
three independent experiments. C) Arrestin-2 and AP-1 bind in response to FPR
activation. Arr2-/-/3-/- FPR cells were transiently transfected with arr2-WT-FLAG
or empty vector and immunoprecipitated with anti-FLAG antibodies after a time
course of FPR activation. Protein was resolved by SDS-PAGE and blotted as
indicated. Representative blots from three independent experiments are shown.

2.8.9. Figure 2.9. FPR recycling upon adaptor protein depletion. A) U937
FPR cells were electroporated with control, AP-1 or AP-2 siRNA. A fraction of
the electroporated cells were harvested before experimentation and lysed for
evaluation of knockdown efficiency. Lysates were resolved by SDS-PAGE and
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blotted with the indicated antibodies. Representative blots are shown. B) U937
FPR cells were treated with the indicated siRNA and assayed for FPR recycling.
FPR recycling was normalized to that of the control siRNA transfected cells.
Control cells internalized 75% of the surface FPR and recycled ~50% of the
internalized

receptor.

recycling/internalization

Data
and

are
are

expressed
representative

as

mean+/of

three

SEM

FPR

independent

experiments. C) U937 FPR cells were transiently transfected with GFP-fused αor γ-subunits. Cells were then stimulated with 546-6pep for the indicated times
and stained with antibodies to α- or γ- subunits (AP-2 or AP-1, respectively).
Cells were imaged by confocal fluorescence microscopy with a 63X objective.
Representative images are shown from three independent experiments. Scale
bars, 10µm.

2.8.10.

Figure 2.10.

Model of FPR post-endocytic trafficking. Following

binding of ligand to the receptor and initial G protein-mediated signaling, the FPR
becomes phosphorylated and internalizes in an arrestin-independent manner.
The FPR nevertheless binds to arrestin either during or shortly after
internalization. AP-2 is then recruited to the FPR-arrestin complex. This occurs
either at some point during its trafficking to the Rab11, perinuclear recycling
endosome or commensurate with or immediately after its arrival at this location.
The FPR/arrestin complex then releases AP-2, either within recycling endosomes
or as the FPR-arrestin complex exits the recycling compartment. Regardless,
AP-1-associated trafficking subsequently results in the FPR/arrestin complex
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exiting the recycling compartment and returning to the cell surface. During this
latter process, the FPR-arrestin complex dissociates and the FPR is
dephosphorylated. Finally, the efferent vesicles fuse with the plasma membrane
completing the recycling of the FPR to the cell surface in a resensitized form
ready to begin signaling anew. This figure was generated using ScienceSlides
(www.visislides.com).

2.8.11. Figure 2.11. Arrestin-2 mutants that do not rescue FPR-mediated
apoptosis are sensitive to caspase inhibitor treatment. Arr2-/-/3-/- FPR cells
were transiently transfected with GFP-fused arrestins and incubated overnight
with 10nM zVAD-FMK (pan-caspase inhibitor). Cells were then stimulated with
10 nM fMLF for 5 hours at 37°C, stained with PI and 100-300 GFP-expressing
cells (from at least five random fields) were viewed and scored for PI staining. In
all cases where FPR-mediated apoptosis occurred, the zVAD-FMK caspase
inhibitor blocked apoptosis. Data expressed as mean ± SEM PI positive/GFP cell
from three independent experiments.

2.8.12. Figure 2.12. Arrestin-2 mutants capable of rescuing apoptosis do
not accumulate in recycling endosomes. Arr2-/-/3-/- FPR cells were transiently
transfected with GFP-fused Rab11 and RFP-fused arrestins and stimulated with
10nM 633-6pep. Cells were imaged by confocal fluorescence microscopy using
a 63X objective. As with cells expressing wild type arrestin-2 or arr2-S412D (cf.
Figure 2.5) all cells expressing mutants that rescued the apoptotic phenotype
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showed the presence of cytoplasmic FPR-arrestin complexes in addition to the
accumulated

FPR-arrestin

complexes

in

the

recycling

compartment.

Representative images are shown and are representative of three experiments.
Scale bars, 10µm.

2.8.13. Figure 2.13. Arrestin-2 mutants differentially colocalize with AP-2.
Arr2-/-/3-/- FPR cells were transiently transfected with RFP-fused arrestins (wild
type, arr2-F391A and arr2-4A) and GFP-fused α-subunit of AP-2. Cells were
stimulated with the 633-6pep ligand for intermediate times (15 and 30 min, cf.
Figure 2.6). Cells were imaged by confocal fluorescence microscopy with a 63X
objective. Representative images are shown and are representative of three
independent experiments. Scale bars, 10µm.

2.8.14. Figure 2.14. Quantitation of AP-2 colocalization with FPR/arrestin
complexes. Rate of AP-2 association with arrestin was determined by viewing
individual cells and ascertaining whether AP-2 clusters were present with
perinuclear arrestin clusters. Data were normalized to the WT response at 60
minutes. Cells were counted from three independent experiments and data are
expressed as the mean AP-2 clusters/arrestin clusters +/- SEM.

2.8.15. Figure 2.15. Antibody staining of AP-2 and AP-1 in U937 FPR cells.
U937 FPR cells were transiently transfected with GFP-fused Rab11. Cells were
then stimulated with 546-6pep for the times indicated and stained with antibodies
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to the α- or γ- subunits (AP-2 or AP-1, respectively). Cells were imaged by
confocal fluorescence microscopy with a 63X objective. Representative images
are shown from three independent experiments. Scale bars, 10µm.
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Figure 2.1. Arrestin domains do not rescue FPR-mediated apoptosis.
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Figure 2.2. Sequence of arrestin-2 carboxy terminus and selected mutants.
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Figure 2.3. Rescue of FPR-mediated apoptosis by arrestin-2 mutants.
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3.1

ABSTRACT
Arrestins were originally described as molecules that bound ligand-

activated, phosphorylated G protein-coupled receptors (GPCR) to block further G
protein signaling.

Subsequently, they were demonstrated to mediate

internalization of the β2-adrenergic and other GPCRs. In addition to blocking G
protein signaling and mediating GPCR internalization, arrestins recruit a number
of signaling proteins including, but not limited to, Src family kinases, ERK1/2, and
JNK3. GPCR-arrestin binding can control the spatial and temporal signaling of
these signaling complexes. In previous reports, we have shown that N-formyl
peptide receptor- (FPR) mediated apoptosis, which occurs upon receptor
stimulation in the absence of arrestins, is associated with receptor accumulation
in the Rab11, perinuclear recycling endosome. Under these conditions, inhibition
of Src kinase and ERK1/2 rescued cells from apoptosis. To better understand
the role of Src kinase in these processes, we used an arrestin-2 mutant deficient
in Src binding (P91G/P121E). Unlike wild type arrestin, this mutant did not inhibit
FPR-mediated apoptosis.

However, cells expressing this mutant could be

rescued by Src kinase inhibition with PP2.

Finally, PP2, while inhibiting

apoptosis in the presence of arr2-P91G/P121E, did not prevent FPR
accumulation in the perinuclear recycling endosome. On the contrary, Src kinase
inhibition by PP2 caused wild type arrestin-2 to accumulate in the recycling
endosome without initiating FPR-mediated apoptosis.

Based on these

observations, we conclude that Src kinase has two independent roles with
respect to arrestin-2 binding in FPR signaling and trafficking.
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3.2

INTRODUCTION
Arrestins were originally described as cytosolic proteins that bound

phosphorylated G protein-coupled receptors (GPCR) (Pierce and Lefkowitz,
2001). Through binding to phosphorylated GPCRs, arrestins sterically block the
binding of heterotrimeric G proteins. This inhibits the GDP-GTP exchange of the
Gα subunit and abates G protein signaling cascades. This was believed to be
their primary function.

Subsequently, arrestins were discovered to mediate

GPCR internalization (Ferguson, 2001). Binding sites for adaptor protein (AP)-2
and clathrin were described within the C-terminus of arrestin (Goodman et al.,
1997; Kim and Benovic, 2002; Milano et al., 2002). Classical GPCRs such as
the beta2-adreneric receptor (β2-AR) (Laporte et al., 1999) and the angiotensin II
(Type 1A) receptor (AT1AR) (Fessart et al., 2005) require arrestin and
subsequent AP-2 and clathrin binding for proper internalization.

In addition,

arrestin-bound Src kinase is also required for proper internalization of the β2-AR
(Luttrell et al., 1999). However, receptors including, but not limited to, the Nformyl peptide receptor (FPR) (Vines et al., 2003) and m2-muscarinic
acetylcholine receptor (Pals-Rylaarsdam et al., 1997) do not require arrestin for
ligand-dependent internalization.
More recently, arrestins have been described as scaffolds for non-G
protein GPCR signaling complexes.

Signaling proteins including Src kinase

(Luttrell et al., 1999), ERK1/2 (Tohgo et al., 2002), JNK3 (McDonald et al., 2000)
bind arrestins and are activated by ligand-bound GPCRs. It is hypothesized that
arrestins recruit activated signaling mediators to activated GPCR signaling
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scaffolds to prevent crosstalk. For example, following β2-AR activation in the
absence of arrestin binding, ERK1/2 is phosphorylated and translocated to the
nucleus where it activates downstream effectors leading to changes in
transcription (Tohgo et al., 2002).

On the other hand, when ERK1/2 is

phosphorylated in the context of a GPCR-arrestin scaffold, activated ERK1/2
remains in the cytosol and activates unknown effector molecules (Kim et al.,
2005; Shenoy et al., 2006). Processes affected by the latter form of ERK1/2
activation are, as of yet, unknown.
Arrestin-Src kinase interaction is the best described of the signaling
scaffolds mentioned above. This interaction is necessary for such processes as
cell migration and degranulation (Luttrell and Luttrell, 2004).

In addition,

disruption of the interaction between arrestin-2 and Src kinase, by mutation of
arrestins, decreased the phosphorylation of ERK1/2 in response to β2-AR
activation (Luttrell et al., 1999). However, this disruption had no affect on ERK1/2
phosphorylation following stimulation of AT1AR.

Finally, proper interaction

between arrestin-2 and Src kinase is required to phosphorylate tyrosine residues
in AP-2 (Fessart et al., 2005). Without phosphorylation of AP-2, the AT1AR does
not internalize in response to activation by ligand.
In the absence of arrestins, FPR activation leads to receptor accumulation
in the Rab11, perinuclear endosomes (Vines et al., 2003) and apoptosis
(Revankar et al., 2004). Apoptosis was rescued by reconstitution of cells with
wild type arrestin-2 or by pretreating cells with inhibitors of Src family kinases,
ERK1/2, JNK3 and p38. In addition, arrestin-2 mutants that have altered binding
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to AP-2 did not rescue apoptosis and prevented recycling from the Rab11
endosome (Chapter 2).
Whereas arrestins control early signaling and trafficking events for many
GPCRs, it has become apparent that arrestins control post-endocytic events of
the FPR. As the interaction between arrestin-2 and Src kinase can mediate both
GPCR internalization via AP-2 and activation of ERK1/2, we hypothesized that
decreased binding of Src kinase to arrestin-2 would lead to FPR accumulation in
the recycling endosome and aberrant activation of ERK1/2 thereby initiating
apoptosis. To this end, we used a mutant of arrestin-2 (arr2-P91G/P121E) that
has been previously described to exhibit decreased binding to Src kinase in
response to β2-AR activation (Luttrell et al., 1999) to better understand the role of
arrestin-2-Src kinase interaction in FPR trafficking and signaling. Our results
demonstrate two independent roles for Src kinase in its association with arrestin2 that independently regulate FPR signaling and trafficking.
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3.3

RESULTS

3.3.1. Src kinase binding-deficient arrestin mutant does not rescue FPRmediated apoptosis.
We have previously shown that FPR-mediated apoptosis is inhibited by
signaling inhibitors of p38, p44/42, JNK and Src family kinases (Revankar et al.,
2004). Arrestins are thought to serve as scaffolds in signaling complexes to
control temporal and spatial signaling (Luttrell and Luttrell, 2003).

To better

understand how arrestins control signaling within the context of FPR activation
and apoptosis, we used a mutant of arrestin-2 that is deficient in Src kinase
binding (arr2-P91G/P121E) (Luttrell et al., 1999). This mutant does not support
ERK1/2 phosphorylation in response to β2-AR activation and inhibits the
internalization of this receptor.
To determine whether arrestin-Src interaction plays a role in FPR
signaling, we examined the arr2-P91G/P121E mutant for its ability to rescue
FPR-mediated apoptosis (Figure 3.1A).

In the absence of ligand, cells

expressing any of the GFP vectors were not stained with propidium iodide (PI)
demonstrating a dependence on receptor activation. Large fractions of arr-2-/--3-/FPR cells expressing EGFP vector (no arrestins present) stained with PI (>90%)
consistent with previous reports (Revankar et al., 2004). In contrast, when arr-2-//-3-/- FPR cells are activated in the presence of wild type arrestin-2-GFP, very few
cells stained with PI (<5%). When arr-2-/-/-3-/- FPR cells are activated in the
presence of this mutant, a large proportion of cells (>90%) stained with PI. This
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led us to conclude that arrestin-Src regulated non-G protein GPCR signaling and
prevented FPR-mediated apoptosis.
Our previous report (Revankar et al., 2004) has described this
phenomenon in detail; including annexin V staining, caspase involvement and PI
staining and these data confirm that this process is FPR- and caspasedependent apoptosis. To confirm that the observed PI staining was apoptosis,
arr-2-/-/-3-/- FPR cells expressing GFP-fused arrestins were assayed for apoptosis
in the presence of zVAD-FMK (pan-caspase inhibitor) (data not shown). Cells
expressing EGFP and arr2-P91G/P121E, were not stained with PI in the
presence of caspase inhibitor (<5%), but were stained at high levels in the
presence of vehicle (>90%). Wild-type arrestin-2 expressing cells did not stain in
either case.

3.3.2. Inhibition of Src kinase rescues FPR-mediated apoptosis in the
presence of the P91G/P121E arrestin mutant.
Overexpression of arr2-P91G/P121E inhibits ERK1/2 activation in
response to β2-AR activation (Luttrell et al., 1999). However, this mutant did not
affect ERK1/2 activation by AT1AR.

These results demonstrated that Src

association with arrestin was selectively required to activate ERK1/2 following
stimulation of the β2-AR. To determine whether Src kinase activity was required
to initiate apoptosis in response to FPR stimulation, independent of arrestin-2, we
used the Src family kinase inhibitor, PP2, (Figure 3.1B). In the arr-2-/-/-3-/- FPR
cells expressing EGFP and the arr2-P91G/P121E mutant <5% stained with PI in
the presence of PP2, while >90% stained in the presence of vehicle. In the arr-294

/-

/-3-/- FPR cells expressing arr2-WT only ~5% stained in the presence of either

vehicle or PP2.
Because PP2 is a general inhibitor of Src family kinases, we confirmed
that our results were due to inhibition of Src kinase activity and not one of the
other family members subject to this inhibitor. Accordingly, arr-2-/-/-3-/- FPR cells
were cotransfected with GFP-fused arrestins and either wild type or kinase dead
(K298M) Src kinase (Figure 3.1C). In the absence of FPR stimulation only ~5%
of the cells stained with PI, indicating apoptosis did not occur. In the presence of
wild type Src kinase, only arr-2-/-/-3-/- FPR cells expressing EGFP or arr2P91G/P121E (>90%) stained with PI, consistent with the above results (Figure
3.1A). In arr-2-/-/-3-/- FPR cells expressing GFP-fused arrestins and kinase dead
Src kinase, <5% cells were stained with PI in response to FPR activation ,
suggesting that Src kinase activity was required to induce the apoptotic
phenotype (Figure 3.1B). These data suggest that although expression of an
arrestin mutant with decreased binding to Src kinase does not rescue apoptosis.
However, inhibition of Src kinase activity with PP2 does rescue apoptosis
indicating that Src kinase signaling does play a role in FPR-mediated apoptosis.

3.3.3. Src kinase does not affect FPR internalization.
FPR internalization is required for FPR-mediated apoptosis in the absence
of arrestins (Revankar et al., 2004). Based on these data, we expected that in
the presence of the arr2-P91G/P121E mutant, the FPR would internalize upon
activation.

Maximum internalization of the FPR in the presence of the arr2-

P91G/P121E mutant is similar to FPR internalization in the presence of EGFP
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and Arr2-WT (Figure 3.2A).

In addition, the rate of FPR internalization was

unaffected (data not shown).

Because PP2 was capable of inhibiting FPR-

mediated apoptosis in the absence of arrestins and presence of Arr2P91G/P121E-GFP, we tested FPR internalization in the presence of GFP-fused
arrestins and PP2. Although Src kinase activity was required for FPR-mediated
apoptosis in the arr-2-/-/-3-/- FPR cells (Revankar et al., 2004) or presence of arr2P91G/P121E-GFP (Figure 3.1B and C) neither PP2 nor vehicle had any effect on
the internalization of the FPR (Figure 3.2B).

These data suggest that FPR-

mediated apoptosis is not being rescued due to inhibition of FPR internalization.

3.3.4. P91G/P121E mutant alters normal FPR trafficking.
FPR-arrestin complex accumulation in the Rab11-positive, perinuclear
recycling endosome correlates directly with FPR-mediated apoptosis (Chapter 2).
To determine whether the arr2-P91G/P121E mutant accumulated in the recycling
endosome, RFP-fused arrestins and GFP-fused Rab11 WT were transiently
expressed in arr-2-/-/-3-/- FPR cells. The FPR was activated with Alexa 633-Nformyl-Leucyl-Leucyl-Phenylalanyl-Leucyl-Tyrosinyl-Lysine (633-6pep) for 1 hour
and ligand-FPR-arrestin complexes were tracked using confocal fluorescence
microscopy (Figure 3.3A). In all cases, arrestin was distributed throughout the
cytosol and Rab11 was localized in a perinuclear location in unstimulated cells
(data not shown, Chapter 2).

In the presence of mRFP1 alone, the FPR

accumulated in the Rab11 compartment with no significant ligand-receptor
complexes present outside this area.

In the presence of arr2-WT-mRFP,

receptor-arrestin complexes were localized to the Rab11 compartment.
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However, significant amounts of receptor-arrestin complexes were present
outside the Rab11 compartment in endocytic vesicles. These phenotypes are
consistent with the FPR’s ability to traffic normally in the presence of wild type
arrestin-2 (Chapter 2).

In the presence of Arr2-P91G/P121E-RFP, receptor-

arrestin complexes accumulate in the Rab11 compartment and very little
receptor-arrestin complex was seen outside this compartment. This is consistent
with the inability of the FPR to recycle and has been hypothesized as an
underlying cause of FPR-mediated apoptosis (Chapter 2).

These results

demonstrate that the arr2-P91G/P121E mutant binds activated receptor.

3.3.5. Inhibition of Src kinase alters normal FPR trafficking.
Because arrestins play a critical role in normal FPR post-endocytic
trafficking (Chapter 2) and FPR-mediated apoptosis was inhibited by PP2 in the
presence of Arr2-P91G/P121E, we hypothesized that PP2 restores normal FPRarrestin complex trafficking. To test this hypothesis, we used transfected arr-2-/-/3-/- FPR cells stimulated in the presence of PP2 or vehicle (Figure 3.3B). Vehicle
did not affect FPR-arrestin trafficking (Figure 3.7A). Use of PP2 demonstrated
no effect on FPR trafficking in the absence of arrestins (mRFP1) as receptor
accumulated in the Rab11 compartment.

Interestingly, PP2 inhibitor did not

affect the trafficking of the FPR in the presence of the P91G/P121E mutant as
receptor-arrestin

complexes

were

retained

in

the

Rab11

endosome.

Furthermore, in the presence of wild type arrestin-2, PP2 lead to accumulation of
the receptor-arrestin complex in the Rab11 recycling endosome. Our results
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suggest Src kinase activity is necessary for normal trafficking of FPR-arrestin
complexes.
To confirm that this was due to inhibition of Src kinase specifically, the
same assay was performed with cells co-transfected with wild type Src kinase or
kinase dead Src kinase. Wild type Src kinase had no effect on the trafficking of
any of the receptor-arrestin complexes (Figure 3.7B) similar to vehicle (Figure
3.7A). The use of kinase dead Src kinase yielded the same results as the use of
PP2 (Figure 3.3C) in which all ligand-FPR-arrestin complexes accumulated in the
Rab11 compartment.

3.3.6. P91G/P121E

arrestin

mutant

alters

FPR

dynamics

with

AP

complexes.
Our previous results demonstrated a role for AP-2 in FPR post-endocytic
trafficking (Chapter 2). In this study, we determined that AP-2 must bind and
release arrestin to allow FPR to exit the perinuclear recycling endosome.
Previous reports demonstrate that Src kinase regulates arrestin-AP-2 interaction
to control AT1AR internalization (Fessart et al., 2005). To better understand the
role of Src kinase in arrestin-AP-2 interaction, we utilized arr-2-/-/-3-/- FPR cells
transfected with the GFP-fused α-subunit of AP-2 and RFP-fused arrestins to
monitor trafficking via confocal fluorescence microscopy (Figure 3.4A). Antibody
staining of the α-subunit of AP-2 confirmed that the α-GFP subunit represented
endogenous AP-2 (Chapter 2).

In unstimulated cells, arrestins showed a

cytosolic distribution with AP-2 which was also present in membrane-associated
puncta, consistent with previous data (data not shown, Chapter 2). In the
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absence of arrestins, following a one hour stimulation of the FPR with 633-6pep,
AP-2 failed to colocalize with FPR in the perinuclear region.

In contrast, as

reported in the presence of wild type arrestin (Chapter 2), AP-2 colocalized with
FPR and arr2-WT in the perinuclear region. Interestingly, in the presence of the
arr2-P91G/P121E mutant, AP-2 colocalized with receptor-arrestin complex in the
perinuclear region suggesting arrestin-AP-2 binding occurs despite the fact that
arrestin may not bind Src kinase.
We have shown that AP-1 colocalizes with receptor-associated vesicles
outside the perinuclear region only in the presence of wild type arrestin-2
(Chapter 2).

Because FPR-arr2-P91G/P121E complexes accumulate in the

perinuclear recycling endosome, we hypothesized that arr2-P91G/P121E would
not colocalize with AP-1 vesicles outside of the recycling endosome consistent
with FPR post-endocytic trafficking in the presence of arrestin mutants that do
not rescue FPR-mediated apoptosis. To test this hypothesis, we used arr-2-/-/-3-/FPR cells transfected with RFP-fused arrestins and the GFP-fused γ-subunit of
AP-1 (Figure 3.4B). Antibody staining of the γ-subunit of AP-1 confirmed that the
γ-GFP subunit reveals the localization of endogenous AP-1 (Chapter 2).

In

unstimulated cells, arrestins were cytosolic and AP-1 was localized in a
perinuclear region consistent with previous data (data not shown, Chapter 2).
When cells were stimulated for 1 hour by 633-6pep in the absence of arrestins
(mRFP1), the FPR accumulated in the AP-1-positive endosome with no little
ligand outside this compartment. In the presence of Arr2-WT, receptor-arrestin
complex was colocalized with AP-1 in a perinuclear region, but receptor-arrestin-
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AP-1 vesicles were also present throughout the cell.

As expected, Arr2-

P91G/P121E colocalized with AP-1 and receptor in the perinuclear region and
not vesicles outside this area consistent with the inhibition of normal FPR
trafficking.

3.3.7. ERK1/2 signaling plays a role in Src- and FPR- mediated apoptosis.
While arr2-P91G/P121E has decreased Src association and inhibits
ERK1/2 activation in response to β2-AR activation, ERK1/2 activation in
response to AT1AR activation is not impaired (Luttrell et al., 1999). In addition,
GPCR-arrestin-Src scaffolds regulate localized activation of ERK1/2 and
therefore other downstream processes (Luttrell and Luttrell, 2003). Because Src
has a clear role in FPR-mediated apoptosis (Figure 3.1) and because ERK1/2
inhibitors can inhibit FPR-mediated apoptosis in the absence of arrestins
(Revankar et al., 2004), we wanted to understand ERK1/2’s role with respect to
the arr2-P91G/P121E mutant.

To this end, we performed apoptosis assays

using arr-2-/-/-3-/- FPR cells transfected with GFP-fused arrestins in the presence
of ERK1/2 inhibitors (Figure 3.5). In the presence of vehicle, apoptosis in cells
transfected with GFP alone and arr2-P91G/P121E-GFP is >90% and with wild
type arrestin-2 is <5% consistent with previous data (Figure 3.1B).

In the

presence of MEK inhibitors U0126 or PD98059, transfected cells did not stain
with PI (<5%) indicating that these inhibitors could stop FPR-mediated apoptosis
in the absence of arrestins or presence of the P91G/P121E mutant.

These

results lead us to hypothesize that Src kinase may be aberrantly activating
ERK1/2 in the absence of arrestin binding.
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3.4

DISCUSSION
Receptor trafficking and signaling are intimately related within the cell and

their proper control is paramount for proper cell function. We have previously
demonstrated that these processes are linked by the fact that arrestin mutants
that alter FPR signaling also alter its post-endocytic trafficking. Previous results
have also suggested a role for Src kinase within these processes. In our present
study, we used an arrestin mutant (P91G/P121E) previously shown to be
defective in binding to Src kinase (Luttrell et al., 1999). We demonstrated that
this mutant was incapable of rescuing FPR-mediated apoptosis, but that cell
death in the presence of this mutant was rescued by inhibition of Src kinase or
ERK1/2 activity. Additionally, this mutant and Src kinase inhibition did not affect
FPR internalization.

Finally, our results indicated that FPR-arr2-P91G/P121E

complexes accumulate in the perinuclear recycling endosome with Rab11, AP-2
and AP-1. Although Src kinase inhibition rescued FPR-mediated apoptosis in the
presence of arr2-P91G/P121E, it did not restore normal trafficking. Interestingly,
Src kinase inhibition caused accumulation of FPR-arr2-WT in the Rab11
endosome without initiating cell death. These results indicate that Src kinase has
two independent roles with respect to arrestin binding: one that controls its
trafficking and one that controls non-G protein FPR signaling.
The most interesting results from our study involve the roles of Src kinasearrestin interaction on FPR trafficking and signaling. The P91G/P121E arrestin
mutant (decreased binding to Src kinase) did not rescue FPR-mediated
apoptosis. However, inhibition of Src kinase and ERK1/2 activity in the presence
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of this mutant did prevent cell death. These results indicate that proper arrestinSrc kinase binding is necessary to control non-G protein FPR signaling.
Interestingly, Src kinase and ERK1/2 are active in the absence of binding to
arrestin-2. Where and how these signaling proteins are being activated by FPR
stimulation is unclear at this time. Perhaps there is unknown, non-G protein
GPCR activation of cellular signaling that is arrestin-independent. Alternatively,
arrestin-2 binding to other proteins not affected by Src kinase binding may
activate these pathways.

For example, the ubiquitous signaling molecule

calmodulin binds arrestins (Wu et al., 2006) and the effects of this binding on
GPCR signaling are currently unknown.
Another interesting result from our study involves the role of arrestin-Src
kinase interaction in FPR trafficking. Our Src kinase-binding deficient arrestin
mutant allowed accumulation of FPR-arrestin complexes in the perinuclear region
with Rab11, AP-2 and AP-1. This is not surprising given the fact that FPRmediated apoptosis and FPR trafficking defects have been linked in previous
work (Chapter 2). However, while Src kinase inhibition rescued FPR-mediated
apoptosis, it did not restore normal FPR-arrestin trafficking.

Furthermore,

inhibition of Src kinase in the presence of wild type arrestin-2 caused FPRarrestin complexes to accumulate in the perinuclear recycling endosome without
initiating apoptosis. These results indicate a role for Src kinase in normal FPR
post-endocytic trafficking. Previous reports have indicated that phosphorylation
of tyrosine residues on AP-2 is necessary to release it from arrestin and mediate
internalization of the AT1AR (Fessart et al., 2005). Additionally, our previous
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results suggest that binding and release of AP-2 from arrestin-2 is necessary to
insure proper post-endocytic trafficking of the FPR (Chapter 2).

Finally, our

results indicate an accumulation of AP-2 with FPR-arrestin in the perinuclear
recycling endosome in the absence of Src kinase activity.

Therefore, we

hypothesize in the absence of arrestin-2 binding or inhibition of its activity, Src
kinase cannot phosphorylate arrestin-bound AP-2 in the perinuclear recycling
endosome.

This leads to accumulation of FPR-arrestin in this region and is

independent of Src kinase’s role in apoptotic signaling.
Finally, our previous results have shown that FPR internalization is not
dependent on clathrin, AP-2, or arrestin (Chapter 2).

In this study, we

demonstrate further that FPR internalization is independent of Src kinase. Our
data demonstrate that FPR internalization extent and rate was not affected by an
arrestin mutant that does not bind Src kinase (P91G/P121E) and use of PP2.
While the factors that control FPR internalization remain unclear at this time,
possible candidates include G protein-receptor kinases and ADP-ribosylation
factor 6. Both of these proteins have shown effects on internalization of the β2AR (Claing et al., 2001) and m2-muscarinic acetylcholine receptor (Roseberry
and Hosey, 2001), respectively.
Based on our results, we present a model for the two independent roles
Src kinase plays in FPR trafficking and signaling (Figure 3.6). In this model,
following ligand binding the FPR activates G proteins which, in turn, activate Src
kinase-mediated apoptotic signaling pathways.

The FPR internalizes in an

arrestin-independent manner. After, or perhaps during internalization, the FPR
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binds arrestin (wild type or P91G/P121E), resulting in the presence of
FPR/arrestin complexes in early endosomes. At some point during its trafficking
to the Rab11, perinuclear recycling endosome (or after its arrival at this location)
the FPR-arrestin complex recruits AP-2. At this point (or earlier), Src kinase is
recruited to the FPR-wild type arrestin-AP2 complex and initiates anti-apoptotic
signaling pathways to counter G protein-mediated apoptotic signaling.

In

addition, Src kinase phosphorylates AP-2 leading to its dissociation from arrestin.
This results in FPR-arrestin egress from the perinuclear recycling endosome.
Along the path to the cell surface the complex dissociates and the FPR is
dephosphorylated. Finally, the FPR completes its return to the cell surface in a
resensitized form ready to continue signaling.

Alternately, FPR-arr2-

P91G/P121E-AP-2 complex accumulates in the perinuclear recycling endosome
due to inability to bind Src kinase without subsequent phosphorylation of AP-2.
This, in turn, inhibits Src kinase from initiating anti-apoptotic signaling within the
context of a GPCR-arrestin signaling scaffold.
This report elucidates two independent roles for Src kinase in FPR
trafficking and signaling. To our knowledge, this is the first indication that Src
kinase has multiple roles within the same GPCR signaling complex: one in
control of its trafficking and one in mediating proper cellular signaling. Both of
these roles are properly regulated with binding to arrestin-2. Our results clarify a
role for arrestin-2 in the spatial and temporal control of non-G protein GPCR
signaling and serve as a model for further study. An interesting question that
arises from this work is: do trafficking defects alter cell signaling or vice-versa?
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We plan to answer this question in the future with further analysis of SH3-binding
domains within arrestin-2 to establish a framework for the regulation of these
processes. With this report of novel roles for arrestins and Src kinase in the
trafficking and signaling of GPCRs, new avenues for the targeting of GPCR
function are presented that may lead to therapeutic interventions for disease
processes.
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3.5

MATERIALS AND METHODS

3.5.1. Materials, Plasmids and Mutagenesis – All materials are from Sigma
unless otherwise specified. Arr2-P91G/P121E-GFP was created by using twostep

PCR

mutagenesis.

Briefly,

primer

GCCCATATGGGCGACAAAGGGACGCGG-3’

pairs

and

5’5’-

GCCCAGCTTCTTGATGAGGCGCTCCTGCAGCCGCGTCAGGGGCTTCTTGTC
CTCACCGGCCGGCGGGAAAGACTGCACG-3’

and

primer

pairs

5’-

GCAGGAGCGCCTCATCAAGAAGCTGGGCGAGCATGCCTACCCTTTCACCTT
TGAGATCCCTGAGAACTCCCATGCTCTGTGACTTTGCAGCCG-3’

and

5’-

GGATCCCGGGCCCATCTGTCGTTGAGCCGCGG-3’ were used to create Nand C-terminal fragments that contain each mutation respectively. Fragments
were purified and amplified using the outside primers to create an Arr2P91G/P121E fragment containing HindIII/ApaI restriction sites.

Standard

subcloning procedures were used to insert this fragment into EGFP or mRFP1
vector.

mRFP1, Arr2-WT-RFP, EGFP, Arr2-WT-GFP, Rab11-WT-GFP, γ-

subunit (AP-1)-GFP and α-subunit (AP-2)-GFP are previously described
(Chapter 2). Murine wild type and kinase dead Src kinase are gifts from Steve
Abcouwer (Upstate Cell Signaling Solutions).

3.5.2. Cell Culture and Transfection – Arr-2-/-/-3-/- FPR cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum, 100
units/mL penicillin and 100units/mL streptomycin at 37°C and 5% CO2. Transient
transfections of arr-2-/-/-3-/- FPR cells were performed with Lipofectamine 2000
according to manufacturer’s instructions.
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3.5.3 Apoptosis – Apoptosis assay was performed as previously described
(Revankar et al., 2004). Briefly, arr-2-/-/-3-/- FPR cells were transiently transfected
and plated on 12mm glass coverslips. The next day, cells were serum-starved
for 30 minutes and incubated with serum-free medium (SFM) for 5 hours with
10nM formyl-methionyl-leucyl-phenylalnine (fMLF) or vehicle at 37°C. Propidium
iodide (PI) was then added to a final concentration of 100pg/μL for 5-10 minutes
at room temperature.

Coverslips were washed and fixed with 2%

paraformaldehyde and mounted using Vectashield. Random fields were viewed
by fluorescence microscopy until 100-300 GFP expressing cells were assayed.
GFP cells were scored for the presence of PI staining. Data are expressed as
mean PI positive/GFP cell.

3.5.4. Internalization – Internalization was performed as previously described
(Vines et al., 2003). Briefly, transiently transfected arr-2-/-/-3-/- FPR cells were
grown to confluence and harvested by trypsinization. Cells were incubated with
1μM fMLF and aliquots were removed to cold SFM at 0, 2, 5, 10, 20 and 30
minutes. Cells were washed extensively with cold SFM to remove excess fMLF.
Cells were then resuspended in cold SFM containing 10 nM Alexa633-N-formylLeucyl-Leucyl-Phenylalanyl-Leucyl-Tyrosinyl-Lysine (633-6pep) and analyzed
using a Becton Dickinson FACSCalibur at appropriate wavelengths. Live cells
were gated using forward- and side-scatter parameters. Cells expressing the
GFP-fused protein of interest were gated using FL-1 and mean channel
fluorescence (MCF) was measured in FL-4 to determine amount of cell surface
receptor. Non-specific background was determined by labeling arr-2-/-/-3-/- cells
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not expressing the FPR with 10nM 633-6pep and assaying as described. Nonspecific binding was subtracted before further analysis. MCF from unstimulated
cells represented 100% FPR cell surface expression. Cell surface expression
from stimulated cells was calculated by dividing the MCF following treatment by
the MCF from unstimulated cells. Internalization data were then plotted using
GraphPad Prism to calculate maximum internalization extents using a one phase
exponential decay.

3.5.5. Confocal Fluorescence Microscopy – Microscopy was performed as
previously described (Vines et al., 2003).

Briefly, arr-2-/-/-3-/- FPR cells were

transiently transfected with plasmids described.

Cells were plated on 25mm

coverslips, grown overnight and serum-starved for 30 minutes. Cells were then
incubated in SFM containing 10nM 633-6pep for the indicated times. Cells were
washed with PBS, fixed with 2% paraformaldehyde and mounted using
Vectashield.

Fluorescence images were acquired using a Zeiss LSM 510

inverted laser scanning microscope equipped with He-Ne and Kr-AR lasers.
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3.6.

FOOTNOTES
We thank Charlotte Vines for helpful comments during the preparation of

this manuscript. Flow cytometry data and confocal images in this study were
generated in the Flow Cytometry and Fluorescence Microscopy Facilities,
respectively, at the University of New Mexico Health Sciences Center, which
received support from NCRR 1 S10 RR14668, NSF MCB9982161, NCRR P20
RR11830, NCI R24 CA88339, the University of New Mexico Health Sciences
Center, and the University of New Mexico Cancer Center. This work was funded
by grant BC030217 from the Department of Defense Breast Cancer Research
Program to B.M.W. and NIH grants AI36357 and GM68901 to E.R.P.
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3.7.

ABBREVIATIONS

AP-1—adaptor protein-1 complex
AP-2—adaptor protein-2 complex
Arr2—arrestin-2
Arr2-/-/3-/- FPR—arrestin-2-/-/-3-/- knockout MEF cells stably expressing the FPR
fMLF—N-formyl-Methionyl-Leucyl-Phenylalanine
FPR—N-formyl peptide receptor
GPCR—G protein-coupled receptor
MEF—mouse embryonic fibroblast
PI—propidium iodide
SFM—serum-free medium (DMEM)
6pep—N-formyl-Leucyl-Leucyl-Phenylalanyl-Leucyl-Tyrosinyl-Lysine
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3.8. FIGURE LEGENDS
3.8.1 Figure 3.1. Inhibition of Src kinase, but not expression of Arr2P91G/P121E, rescues FPR-mediated apoptosis. Arr-2-/-/-3-/- FPR cells were
transiently transfected with constructs described, stimulated with 10nM fMLF and
stained with PI. Random fields were viewed by fluorescence microscopy until
100-300 cells GFP cells were counted. GFP cells were scored for the presence
of PI staining. Data are expressed as mean PI positive/GFP cell +/- SEM from
three independent experiments.

A) Arr-2-/-/-3-/- FPR cells were transiently

transfected with GFP-fused arrestins. B) Arr-2-/-/-3-/- FPR cells were transiently
transfected with GFP-fused arrestins and incubated with DMSO or PP2 (10nM,
30 min) before and during stimulation. C) Arr-2-/-/-3-/- FPR cells were transiently
transfected with GFP-fused arrestins and either wild type Src kinase or kinase
dead (K298M) Src kinase.

3.8.2 Figure 3.2. FPR internalization is not affected by arrestins or Src
inhibition. A) Arr-2-/-/-3-/- FPR cells were transiently transfected with GFP-fused
arrestins and assayed for internalization. Data are expressed as mean maximum
internalization +/- SEM from three independent experiments. B) Arr-2-/-/-3-/- FPR
cells were transiently transfected with GFP-fused arrestins, pre-incubated with
PP2 (10nM, 30 min) and assayed for internalization in the presence of inhibitor.
Data are expressed as mean maximum internalization +/- SEM from three
independent experiments.

3.8.3. Figure 3.3. FPR-arrestin complexes traffic differentially with Rab11
in response to Src inhibition.

Arr-2-/-/-3-/- FPR cells were transiently

transfected with constructs listed individually below. Cells were stimulated with
111

10nM 633-6pep for 1 hour and viewed by confocal fluorescence microscopy.
Images are representative of three independent experiments. A) Arr-2-/-/-3-/- FPR
cells were transfected with RFP-fused arrestins and GFP-fused Rab11-WT. B)
Arr-2-/-/-3-/- FPR cells were transiently transfected with RFP-fused arrestins and
GFP-fused Rab11-WT. Cells were incubated with PP2 (10nM, 30min) before
and during stimulation C) Arr-2-/-/-3-/- FPR cells were transiently transfected with
GFP-fused Rab11-WT, RFP-fused arrestins and kinase dead Src kinase.

3.8.4. Figure 3.4.
and AP-1.

FPR-arrestin complexes traffic differentially with AP-2

Arr-2-/-/-3-/- FPR cells were transiently transfected with constructs

described. Cells were stimulated with 10nM 633-6pep for 1 hour and viewed by
confocal fluorescence microscopy.

Images are representative of three

independent experiments. A) Arr-2-/-/-3-/- FPR cells were transfected with RFPfused arrestins and GFP-fused α-subunit of AP-2. B) Arr-2-/-/-3-/- FPR cells were
transiently transfected with RFP-fused arrestins and GFP-fused γ-subunit of AP1.

3.8.5. Figure 3.5. FPR-mediated apoptosis in the absence of arrestins or
presence of P91G/P121E is sensitive to ERK inhibition. Arr-2-/-/-3-/- FPR cells
were transiently transfected with GFP-fused arrestins and pre-incubated with
U0126 (10μM, 30 min), PD98059 (25μM, 30 min) or DMSO.

Cells were

stimulated with 10nM fMLF and stained with PI. Five random fields were viewed
by fluorescence microscopy until 100-300 cells GFP cells were counted. GFP
cells were scored for the presence of PI staining. Data are expressed as mean
PI positive/GFP cell +/- SEM from three independent experiments.
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3.8.6. Figure 3.6.

Role of Src kinase in FPR trafficking and signaling.

Based on our results, we present a model for the two independent roles Src
kinase plays in FPR trafficking and signaling. In this model, following ligand
binding the FPR activates G proteins which, in turn, activate Src kinase-mediated
apoptotic signaling pathways. The FPR internalizes in an arrestin-independent
manner. After, or perhaps during internalization, the FPR binds arrestin (wild
type or P91G/P121E), resulting in the presence of FPR/arrestin complexes in
early endosomes. At some point during its trafficking to the Rab11, perinuclear
recycling endosome (or after its arrival at this location) the FPR-arrestin complex
recruits AP-2. At this point (or earlier), Src kinase is recruited to the FPR-wild
type arrestin-AP2 complex and initiates anti-apoptotic signaling pathways to
counter G protein-mediated apoptotic signaling.

In addition, Src kinase

phosphorylates AP-2 leading to its dissociation from arrestin.

This results in

FPR-arrestin egress from the perinuclear recycling endosome. Along the path to
the cell surface the complex dissociates and the FPR is dephosphorylated.
Finally, the FPR completes its return to the cell surface in a resensitized form
ready to continue signaling. Alternately, FPR-arr2-P91G/P121E-AP-2 complex
accumulates in the perinuclear recycling endosome due to inability to bind Src
kinase without subsequent phosphorylation of AP-2. This, in turn, inhibits Src
kinase from initiating anti-apoptotic signaling within the context of a GPCRarrestin signaling scaffold.

This figure was generated using ScienceSlides

(www.visislides.com).
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3.8.7. Figure 3.7.

Vehicle and Src wild type do not alter FPR-arrestin

trafficking phenotypes. Arr-2-/-/-3-/- FPR cells were transiently transfected with
constructs listed individually below. Cells were stimulated with 10nM 633-6pep
for 1 hour and viewed by confocal fluorescence microscopy.

Images are

representative of three independent experiments. A) Arr-2-/-/-3-/- FPR cells were
transiently transfected with RFP-fused arrestins and GFP-fused Rab11-WT.
Cells were incubated with PP2 (10nM, 30min) before and during stimulation B)
Arr-2-/-/-3-/- FPR cells were transiently transfected with GFP-fused Rab11-WT,
RFP-fused arrestins and kinase dead Src kinase.
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Figure 3.3A. FPR-arrestin complexes traffic differentially with Rab11.
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Figure 3.3B. FPR-arrestin complexes traffic differentially with Rab11 in response to Src
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Figure 3.3C. FPR-arrestin complexes traffic differentially with Rab11 in response to Src
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4.1

ABSTRACT
Arrestin binding to Src kinase is an important event that regulates

localized activation of MAPK signaling cascades and cellular proliferation. This
interaction is controlled by SH3-binding domains (P-X-X-P) within arrestin at
three locations: P88/P91, P121/P124 and P175/P178. When this interaction is
disrupted by mutation of prolines within SH3-binding domains, ERK1/2 activation
is decreased upon activation of the β2-adrenergic receptor. In a recent report,
we demonstrated that arrestin-Src kinase interaction was vital to proper
regulation of N-formyl peptide receptor- (FPR) mediated signaling, trafficking and
apoptosis. We elucidated two roles for arrestin-Src kinase interaction in these
processes. First, Src kinase was hypothesized to control trafficking of the FPR
by phosphorylating tyrosine resides in the adaptor protein (AP)-2 complex to
release AP-2 from arrestin and allow egress of the FPR from the perinuclear
recycling endosome. Second, Src kinase activity was also necessary to mediate
FPR-mediated apoptosis independent of FPR trafficking. An important question
that arose from this work was whether altered trafficking of the FPR lead to
aberrant Src kinase-MAPK signaling or vice-versa. In order to understand the
mechanisms of FPR trafficking and signaling that lead to FPR-mediated
apoptosis, we generated three mutants of arrestin-2 in which prolines within SH3binding domains were replaced with alanine.

Our studies demonstrate two

important results. First, arrestin-Src kinase binding is necessary to rescue FPRmediated apoptosis and one SH3-binding domain (P88-X-X-P91) controls this
phenotype. Second, as FPR trafficking was not altered in the presence of any of
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the arrestin mutants used in this study, we conclude that altered FPR signaling
can occur without altered FPR trafficking.

This study elucidates important

mechanisms in G protein-coupled receptor (GPCR) signaling and trafficking
which will give insight to mechanisms of temporal and spatial control of GPCR
signaling complexes.
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4.2

INTRODUCTION
Arrestins are cytosolic proteins that have roles in mediating G protein-

coupled receptor (GPCR) desensitization, internalization and non-G protein
scaffold signaling (Reiter and Lefkowitz, 2006). These functions are controlled
by arrestin binding to ligand-activated, C-terminal phosphorylated GPCRs,
clathrin, adaptor protein (AP)-2 and Src kinase (Lefkowitz and Shenoy, 2005).
Arrestin binding to these cellular components controls both the temporal and
spatial signaling of GPCRs (Luttrell and Luttrell, 2003). This, in turn, regulates
various cellular functions including proliferation and migration.
Arrestin-Src kinase interaction is vital for mediating activation of
extracellular-regulated kinase (ERK) 1/2 (Luttrell et al., 1999).

When cells

expressing the β2-adrenergic receptor (β2-AR) were transiently transfected with
an arrestin mutant that exhibited decreased binding to Src kinase, ERK1/2
activation was decreased in response to stimulation with isoproterenol.
arrestin mutant also inhibited the internalization of the β2-AR.

This

Interestingly,

ERK1/2 activation was not affected when cells expressing the angiotensin II
(Type 1A) receptor (AT1AR) were transfected with the same arrestin mutant and
stimulated with angiotensin II.
An indirect interaction between Src kinase and arrestin also controls
internalization of GPCRs.

When arrestin and AP-2 were not allowed to

dissociate, internalization of the AT1AR was inhibited (Fessart et al., 2005). The
authors went on to demonstrate that phosphorylation of tyrosine resides within
AP-2 was necessary for arrestin and AP-2 to dissociate and internalization of the
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AT1AR to occur. Given that binding of AP-2 and arrestin are also necessary for
proper GPCR internalization (Laporte et al., 1999), these results indicate that Src
kinase plays an intimate role in arrestin-AP-2 interaction cycling.
Our previous results demonstrate that arrestin-Src kinase interaction is
required for rescue of cells from N-formyl peptide receptor- (FPR) mediated
apoptosis (Revankar et al., 2004). In addition, we showed that inhibition of Src
kinase with PP2 could rescue FPR-mediated apoptosis, but not the associated
trafficking defects (Chapter 3). In fact, inhibition of Src kinase activity led to
aberrant FPR trafficking in the presence of wild type arrestin without initiating
apoptosis. This result led us to believe that Src kinase plays two independent,
arrestin-associated roles in FPR signaling and trafficking. One role is involved
with control of FPR post-endocytic trafficking by phosphorylating AP-2 to allow its
dissociation from arrestin and receptor egress from the perinuclear recycling
endosome.

The other role is to regulate proper FPR non-G protein scaffold

signaling to prevent FPR-mediated apoptosis.
Our results were complicated by the fact that the arrestin-2 (arr2) mutant
deficient in Src kinase binding contained mutations in individual SH3-binding
domains (P91G and P121E). Therefore this led us to ask an important question
in GPCR trafficking and signaling: Do GPCR signaling defects initiate GPCR
trafficking defects or vice-versa? In order to answer this question, we further
evaluated the role of SH3-binding domains (P-X-X-P) within arrestin-2 (P88/P91,
P121/P124 and P175/P178). Prolines were mutated to alanine within individual
SH-3 domains and evaluated for their ability to alter FPR-mediated signaling and
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trafficking. In addition, arrestin mutants were designed that mimic the original
arrestin mutant that has decreased binding to Src kinase to insure that our
results were not due to changes in the secondary structure of arrestin-2 due to
replacement of prolines with alanine.

Our results demonstrate that altered

arrestin-Src kinase interaction can alter FPR signaling without changing its
normal trafficking.

These results suggest that GPCR signaling may control

GPCR trafficking, at least within the context of the FPR.
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4.3

RESULTS

4.3.1. Mutations in SH3-binding domains of arrestin have differential
effects on FPR-mediated apoptosis.
Previous results have demonstrated that mutation of individual prolines
within multiple SH3-binding domains (P91G/P121E) do not rescue FPR-mediated
apoptosis and cause receptor-arrestin complexes to accumulate within the
Rab11, perinuclear recycling endosome (Chapter 2). To better understand the
role of arrestin-Src kinase interaction in FPR signaling and trafficking we
generated three mutants of arrestin that mutated prolines in SH3-binding
domains (P-X-X-P) to alanine (P88A/P91A, P121A/P124A and P175A/P178A).
This method of analysis allows us to assess the individual contributions of
arrestin-2 SH-3 binding to Src kinase in FPR signaling and trafficking.
Mouse embryonic fibroblasts (MEF) deficient in both arrestin-2 and -3, but
stably expressing the FPR (arr2-/-/3-/- FPR), were used to assess arrestin-2
mutants in the absence of competition from endogenous arrestins. Arr2-/-/3-/FPR cells were transiently transfected with empty GFP vector, arr2-WT-GFP and
GFP-fused arrestin mutants and assayed for rescue of FPR-mediated apoptosis
(Figure 3.1A).

Our use of propidium iodide (PI) staining has been validated

previously (Revankar et al., 2004) as an accurate method of monitoring
apoptosis. When GFP expressing cells were unstimulated, <10% of cells were
stained with PI consistent with previous results exhibiting that apoptosis is FPRdependent. When cells expressing empty GFP vector (absence of arrestins)
were stimulated with N-formyl-Methionyl-Leucyl-Phenylalanine (fMLF), >90% of
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cells stained with PI. However, cells expressing arr2-WT-GFP stained <10% with
PI consistent with the ability of arrestin-2 to rescue FPR-mediated apoptosis.
Arr2-/-/3-/- FPR cells expressing GFP-fused mutants demonstrated differential
ability to rescue FPR-mediated apoptosis. Arrestin-2 mutants with alterations in
the first (P88A/P91A) and third (P175A/P178A) SH3-binding domains rescued
FPR-mediated apoptosis (<10% PI staining. However, in cells expressing arr2P121A/P124A-GFP, >90% of cells stained with PI.

This indicates that the

second SH3-binding domain of arrestin is responsible for regulating Src kinase
binding and preventing FPR-mediated apoptosis.
To confirm that our results were due to activation of Src kinase in the
absence of arrestin binding, we transiently transfected arr2-/-/3-/- FPR cells with
empty GFP vector, arr2-WT-GFP and arr2-P121A/P124A-GFP and inhibited Src
kinase activity (with PP2, a Src family kinase inhibitor) during FPR stimulation
(Figure 3.1B). In the presence of vehicle, empty GFP and arr2-P121A/P124AGFP >90% transfected cells stained with PI while <10% of cells transfected with
arr2-WT-GFP stained with PI. When cells were incubated with PP2, <10% of
GFP cells stained with PI in all conditions. These results indicate that although
Src kinase binding to arrestin may be decreased due to mutation of one of
arrestin-2’s SH3-binding domains, Src kinase activity initiates apoptotic signaling.

4.3.2. Rescue of FPR-mediated apoptosis by SH3-binding arrestin mutants
is not due to inhibition of internalization.
In a previous report, a signaling competent, internalization-defective FPR
mutant was incapable of initiating FPR-mediated apoptosis (Revankar et al.,
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2004). Because internalization is required to initiate FPR-mediated apoptosis,
we hypothesized those SH3-binding mutants that rescue FPR-mediated
apoptosis may inhibit FPR internalization. To test this hypothesis, we transfected
arr2-/-/3-/- FPR cells with GFP-fused arrestins and measured FPR internalization.
FPR internalization extents were 60-70% for all GFP conditions (Figure 3.2) and
rates of internalization were also similar (data not shown). Therefore, rescue of
FPR-mediated apoptosis by SH3-binding mutants is not due to inhibition of FPR
internalization.

4.3.3. SH3-binding mutants allow normal FPR trafficking.
Previous reports reveal FPR trafficking defects associated with arrestin-2
mutants that do not rescue FPR-mediated apoptosis including mutation in AP-2
binding

domains

(F391A,

(P91G/P121E—Chapter 3).

4A—Chapter2)

and

Src-binding

domains

These arrestin mutants accumulate in the

perinuclear recycling endosome, with little receptor-arrestin complex seen
outside this location. Therefore, we hypothesized the arr2-P121A/P124A mutant
would accumulate with the FPR in the Rab11, perinuclear recycling endosome.
To test this hypothesis, arr2-/-/3-/- FPR cells were transfected with RFP-fused
arrestins and Rab11-GFP and viewed by confocal fluorescence microscopy
(Figure 3.3). In unstimulated cells, Rab11 is localized in a perinuclear location
and arrestins are distributed throughout the cytosol consistent with a lack of FPR
stimulation. When the FPR is stimulated with Alexa 633-N-formyl-Leucyl-LeucylPhenylalanyl-Leucyl-Tyrosinyl-Lysine (633-6pep) in the absence of arrestins
(empty vector), ligand-FPR complexes accumulate in the Rab11 endosome with
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little to no ligand outside this location (data not shown).

When cells are

transfected with mRFP-fused wild type arrestin-2 and stimulated with 633-6pep,
ligand-FPR complexes are colocalized with the Rab11 endosome (data not
shown). However, ligand-FPR complexes are distributed in vesicles throughout
the cytosol. These phenotypes are consistent with previously published results
(Chapter 2, (Vines et al., 2003). Interestingly, cells transfected with SH3-binding
mutants are stimulated, all mutants have ligand-receptor complexes in vesicles
within the cytosol as well as colocalized with the Rab11 endosome. Our results
imply that while the arr2-P121A/P124A mutant does not rescue FPR-mediated
apoptosis, it does allow normal trafficking of the FPR.
AP complexes demonstrate differential trafficking patterns with FPRarrestin signaling complexes (Chapter 2).

AP-2 either accumulates with

receptor-arrestin complexes in the Rab11 endosome or does not bind these
complexes at all. AP-1 does colocalize with all mutants in the Rab11 endosome,
but is only in vesicles outside this location with the FPR in the presence of wild
type arrestin-2. We hypothesized that while FPR-SH3-binding mutants traffic
normally with respect to the Rab11 compartment, they may have altered
trafficking with either of the AP complexes.
Arr2-/-/3-/- FPR cells were transfected with RFP-fused arrestins and either
α-GFP and viewed by confocal fluorescence microscopy (AP-2, Figure 3.4A) or
γ-GFP (AP-1, Figure 3.4B).

In unstimulated cells, arrestins have a cytosolic

distribution, AP-2 has some protein in the cytosol with most in puncta within the
cell membrane and AP-1 is localized in a perinuclear region. In cells expressing
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empty vector and stimulated with 633-6pep, AP-2 did not colocalize with ligandFPR complexes in the perinuclear region. While AP-1 did colocalize with FPR in
the perinuclear region, neither AP-1 nor ligand-FPR was outside this location
(data not shown). When cells were stimulated with 633-6pep in the presence of
wild type arrestin, both AP-2 and AP-1 colocalized with FPR-arrestin complexes
in the perinuclear region. In addition, ligand-FPR-AP-1 complexes were localized
outside the perinuclear region consistent with normal FPR trafficking. These
phenotypes are consistent with previously published data (data not shown,
Chapter 2). Once again, in the presence of all RFP-fused SH3-binding arrestin
mutants, FPR-arrestin trafficking was similar to that of wild type arrestin-2. When
stimulated, AP-2 and AP-1 were colocalized with FPR-arrestin complexes in the
perinuclear region.

However, FPR-arrestin-AP-1 complexes were trafficking

outside the perinuclear region.

4.3.4. Individual SH-3 binding point mutations in arrestin differentially
regulate FPR-mediated apoptosis.
In previous reports demonstrating that arrestin-Src kinase interaction
regulate FPR trafficking and signaling (Chapter 3), we used a mutant containing
individual point mutations within different SH3-binding domains.

In previous

sections, we have demonstrated that the second SH3-binding domain
(P121/P124) alters FPR signaling by not rescuing FPR-mediated apoptosis, but
demonstrated no effect on FPR trafficking. To remove the possibility that our
results are due to mutations within SH3-binding domains that decrease arrestinSrc kinase binding and not alteration of arrestin-2 secondary structure, two
135

arrestin-2 mutants were generated with single point mutations (P91G and
P121E). These mutants contain the same mutations as previous SH3-binding
mutants described (P91G/P121E). However, they are done individually to more
accurately describe the role of SH3-binding domains of arrestin-2 in FPR
signaling and trafficking.
Arr2-/-/3-/- FPR cells were transfected with GFP-fused arrestin point
mutations and assayed for rescue of FPR-mediated apoptosis (Figure 3.5A). In
unstimulated GFP-expressing cells, there is <10% PI staining. When the FPR is
activated with fMLF, arr2-WT and arr2-P91G rescue apoptosis (<10% PI
staining). However, empty GFP and arr2-P121E cells were >90% PI positive.
These results confirm that FPR-mediated apoptosis is due to mutations within the
P121/P124 SH3-binding domain and not due to alteration of arrestin-2 secondary
structure.
To confirm that Src kinase activity was necessary to initiate FPR-mediated
apoptosis in the presence of the arr2-P121E mutant, arr2-/-/3-/- FPR cells
expressing GFP-fused arrestins were assayed for apoptosis while incubated with
PP2 (Figure 3.5B). In GFP cells incubated with vehicle, FPR activation did not
rescue FPR-mediated apoptosis in the absence of arrestins (empty vector) or the
presence of arr2-P121E >90% PI staining). Arr2-WT did rescue FPR-mediated
apoptosis when incubated with vehicle (<10% PI staining). In the presence of
PP2, all GFP cells were rescued from FPR-mediated apoptosis (<10% PI
staining).
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4.3.5. FPR internalization is not affected by arrestin-2 point mutations.
As

previously

mentioned,

FPR-mediated

apoptosis

requires

FPR

internalization. Arr2-/-/3-/- FPR cells were transfected with GFP-fused arrestins
and FPR internalization was evaluated (Figure 3.6). In all GFP-expressing cells,
FPR internalization extent varies between ~65-70% and rates of FPR
internalization were similar (data not shown). These data indicate that rescue of
FPR-mediated apoptosis is not due to inhibition of its internalization.

4.3.6. Arrestin-2 SH-3 binding domain point mutations do not alter FPR
trafficking.
To assess that normal FPR trafficking allowed by an arrestin mutant
(P121A/P124A) was due to mutation of the SH3-binding domain and not due to
alterations of arrestin-2 secondary structure, we assayed arr2-/-/3-/- FPR cells
expressing arrestin-2 point mutants fused to RFP for FPR trafficking with Rab11GFP by confocal fluorescence microscopy (Figure 3.7). When the FPR was
stimulated, both arrestin-2 point mutants colocalize with ligand-FPR in the Rab11
endosome.

In addition, FPR-arrestin complexes were localized in vesicles

outside the perinuclear region consistent with normal FPR trafficking (Chapters 2
and 3, (Vines et al., 2003).
To ascertain whether FPR and AP complexes traffic normally with arrestin
SH3-binding point mutants, we used confocal fluorescence microscopy. Arr2-/-/3/-

FPR cells were transfected with RFP-fused arrestins and either α-GPF or γ-

GFP (Figures 3.8A and 3.8B, respectively). Upon stimulation of the FPR ligandFPR-arrestin point mutant complexes colocalize with AP-2 and AP-1 in the
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perinuclear region. Additionally, FPR-arrestin-AP-1 complexes are localized in
vesicles outside the perinuclear region consistent with previous data evaluating
normal FPR trafficking (Chapters 2 and 3).
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4.4.

DISCUSSION
Proper temporal and spatial control of GPCR signaling complexes is vital

to proper cellular function.

We have previously shown that FPR-mediated

apoptosis is linked to receptor-arrestin accumulation in the perinuclear recycling
endosome (Chapter 2). Additionally, we have demonstrated that two roles for
Src kinase are involved in this process (Chapter 3). However, the Src bindingdeficient mutant used in this work contained two point mutations in different SH3binding domains of arrestin-2. An important question that arose from this work is
whether altered FPR trafficking led to aberrant FPR signaling or vice-versa. We
hypothesized that individual SH3-binding domains within arrestin-2 may be
responsible cause aberrant trafficking and signaling sequentially. Our results
indicate this is not the case.
In experiments to assay the effect of mutation of individual SH3-binding
domains of arrestin-2 (P88A/P91A, P121A/P124A and P175A/P178A), we found
the second SH3-binding domain (P121A/P124A) did not rescue FPR-mediated
apoptosis. However, none of the mutants assayed altered FPR internalization of
post-endocytic

trafficking.

FPR-mediated

apoptosis

allowed

by

the

P121A/P124A mutant was rescuable by inhibition of Src kinase activity. Because
use of alanine to replace prolines within the SH3-binding domains could
significantly alter arrestin-2 secondary structure, we also generated point mutants
of arrestin-2 (P91G and P121E) that were exactly like the original mutant used
(P91G/P121E, Chapter 3), but with mutation of only one SH3-binding domain at
a time. The P121E mutant did not rescue FPR-mediated apoptosis (although
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this was rescued by Src kinase inhibition) and neither mutant altered FPR
trafficking.
These results suggest that FPR signaling and trafficking may operate
independently (within the context of arrestin-Src kinase binding) rather than
causally. Clearly, the second SH3-bindng domain (P121/P124) is responsible for
regulating FPR signaling complexes. However, it does not alter FPR trafficking.
Additionally, the first domain (P88/P91) has no effect on FPR signaling and
trafficking when mutated. It is only when both SH3-binding domains are mutated
(P91G/P121E, Chapter 3) that defects in both FPR signaling and trafficking
occur. This implies that Src kinase binding to either domain properly regulates
FPR post-endocytic trafficking while mutation of the second domain (P121/P124)
is sufficient to alter FPR signaling. Only when both domains are mutated, are
alterations observed. A role for the third domain (P175/P178) is unclear at this
time. By itself, this domain is not sufficient to rescue FPR from signaling and
trafficking defects.

However, its mutation does not alter FPR function in the

assays we used. It is possible that this domain regulates some other function of
FPR signaling or trafficking such as migration or degranulation.
Our findings elucidate differences in the regulation of FPR trafficking and
signaling. Previously, we hypothesized a causal link between receptor-arrestin
accumulation in the perinuclear recycling endosome and FPR-mediated
apoptosis. However, our findings indicate this is not the case. It is clear that
FPR signaling defects can occur independently of trafficking defects. Whether
the opposite is true is unknown at this time. This report further elucidates the
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intimate and intricate dualities of GPCR trafficking and signaling. Other GPCRs,
such as the β2-AR (Daaka et al., 1998), and receptor tyrosine kinases, such as
the epidermal growth factor (Vieira et al., 1996) receptor also demonstrate a
causal link between receptor internalization and ERK1/2 activation. Is it possible
that trafficking and signaling can be altered independently of one another in
these systems? The implication that receptor trafficking and signaling can be
modified independently of other processes creates new avenues for the targeting
of GPCR function that may lead to novel therapeutic interventions for disease
processes.
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4.5.

MATERIALS AND METHODS

4.5.1. Plasmids
Empty GFP vector, Arr2-WT-GFP, Rab11-WT-GFP, γ-GFP (AP-1), α-GFP (AP2), empty mRFP1 vector and Arr2-WT-RFP have been previously described
(Chapter 2).

Arrestin-2 mutants (P88A/P91A, P121A/P124A, P175A/P178A,

P91G and P121E) were generated by site-directed mutagenesis using
QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene) using Arr2-WTGFP as the staring construct. RFP-fused arrestin-2 mutants were generated
standard subcloning procedures and HindIII/ApaI restriction sites.

4.5.2. Cell Culture and Transfection
Arr2-/-/3-/- FPR cells were grown in DMEM with 10% fetal bovine serum, 100
units/mL penicillin and 100units/mL streptomycin at 37°C and 5% CO2. Transient
transfections of arr2-/-/3-/- FPR cells were performed with Lipofectamine 2000
according to manufacturer’s instructions.

4.5.3. Apoptosis
Apoptosis of arr2-/-/3-/- FPR cells was performed as previously described
(Revankar et al., 2004). Briefly, arr2-/-/3-/- FPR cells were transiently transfected
with GFP-fused arrestins. Cells were then plated to 12mm glass coverslips and
serum-starved for 30min. Cells were then stimulated with 10nM fMLF for 5 hours
at 37°C. Propidium iodide (PI) was added to a final concentration of 100ng/mL
for 5-10min at room temperature.

Cell were washed with PBS, fixed and

mounted with Vectashield. Slides were viewed by fluorescence microscopy and
random fields were evaluated (at least five) until 100-300 GFP-expressing cells
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were assayed. GFP-expressing cells were counted “positive” for cell death if
they were stained with propidium iodide. Data are expressed as a percentage of
PI-positive/GFP-expressing cells. For assays in which inhibitor was used, cells
were treated with 10nM PP2 during serum-starvation and treatment remained
throughout FPR stimulation.

4.5.4. Internalization
FPR internalization was assayed as previously described (Vines et al., 2003).
Briefly, arr2-/-/3-/- FPR cells were transiently transfected with GFP-fused arrestins.
Cells were harvested and resuspended in serum-free medium (SFM). The FPR
was stimulated with 1μM fMLF and aliquots were removed at 3, 6, 10, 20 and
30min and added to pre-chilled SFM.

One aliquot was removed before

stimulation to measure total cell surface receptor. Cells were washed extensively
with cold SFM to remove excess unlabelled ligand.

Remaining cell surface

receptor was labeled with 10nM 633-6pep and assayed by flow cytometry using
a Becton-Dickinson FACSCalibur. For analysis, cells live cells were gated using
forward- and side-scatter parameters.

Cells were then gated for arrestin

expression using FL-1. Mean channel fluorescence (MCF) was then measured
using FL-4. Non-specific binding was determined by labeling arr2-/-/3-/- FPR cells
not expressing the FPR and this value was subtracted from all internalization
values. Unstimulated cells were considered to have 100% cell surface receptor.
Cell surface expression of stimulated cells was calculated by dividing its MCF by
the MCF of the corresponding unstimulated cells. Internalization data were then

143

plotted using GraphPad Prism to calculate maximum internalization extents using
a singe exponential decay.

4.5.5. Confocal Fluorescence Microscopy
Confocal microscopy was performed as previously described (Vines et al., 2003).
Briefly, arr2-/-/3-/- FPR cells were transiently transfected with RFP-fused arrestins
and GFP-fused Rab11, AP-1 or AP-2. Cells were plated to 25mm coverslips and
serum-starved for 30min. Cells were stimulated with 10nM 633-6pep for 1 hour
at 37°C in SFM. Cells were washed with PBS, fixed with 2% paraformaldehyde
and mounted using Vectashield. Fluorescence images were acquired using a
Zeiss LSM 510 inverted laser scanning microscope equipped with He-Ne and KrAR lasers.
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4.7.

ABBREVIATIONS

AP-1—adaptor protein-1 complex
AP-2—adaptor protein-2 complex
Arr2—arrestin-2
Arr2-/-/3-/- FPR—arrestin-2-/-/-3-/- knockout MEF cells stably expressing the FPR
fMLF—N-formyl-Methionyl-Leucyl-Phenylalanine
FPR—N-formyl peptide receptor
GPCR—G protein-coupled receptor
MEF—mouse embryonic fibroblast
PI—propidium iodide
SFM—serum-free medium (DMEM or RPMI)
6pep—N-formyl-Leucyl-Leucyl-Phenylalanyl-Leucyl-Tyrosinyl-Lysine
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4.8.

FIGURE LEGENDS

4.8.1. Figure 4.1. Rescue of FPR-mediated apoptosis by arrestin-2 SH3binding mutants. A) Arr2-/-/3-/- FPR cells transiently transfected with GFP-fused
arrestin mutants were assayed for apoptosis. Cells were stained with PI and
100-300 GFP-expressing cells were viewed and scored for the presence of PI
staining.

Data expressed as mean ± SEM PI positive/GFP cell from three

independent experiments. B) Arr-2-/-/-3-/- FPR cells were transiently transfected
with GFP-fused arrestins and incubated with DMSO or PP2 (10nM, 30 min)
before and during stimulation.

4.8.2. Figure 4.2. Internalization of the FPR in presence of arrestin-2 SH3binding mutants. Arr2-/-/3-/- FPR cells transiently transfected with GFP-fused
arrestins were stimulated with 1µM fMLF and aliquoted at multiple time points.
Cells were washed free of fMLF, labeled with 633-6pep and analyzed by flow
cytometry for residual cell surface receptor.

Cells were gated for GFP

expression (FL1) to restrict the analysis to transfected cells. Data are expressed
as the maximum extent of internalization based on curve fitting using a single
exponential decay. Data are expressed as mean ± SEM from three independent
experiments.

4.8.3. Figure 4.3.

Arrestin-2 SH3-binding mutants traffic normally with

respect to Rab11. Arr2-/-/3-/- FPR cells were transiently transfected with GFPfused Rab11 and RFP-fused arrestins and plated on coverslips.

Cells were

stimulated with the 633-6pep for 1 hour at 37°C and imaged by confocal
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fluorescence microscopy.

Representative images are shown from three

independent experiments.

4.8.4. Figure 4.4. Arrestin-2 SH3-binding mutants traffic normally with AP-2
and AP-1. A) Arr2-/-/3-/- FPR cells were transiently transfected with RFP-fused
arrestins and the GFP-fused α-subunit of AP-2.

Cells were subsequently

stimulated with 633-6pep at 37°C for the indicated time and imaged by confocal
fluorescence microscopy.

Representative images are shown from three

independent experiments. B) Arr2-/-/3-/- FPR cells were transiently transfected
with RFP-fused arrestins and the GFP-fused γ-subunit of AP-1. Cells were then
stimulated with the 10nM 633-6pep ligand, fixed and viewed by confocal
fluorescence microscopy.

Representative images are shown from three

independent experiments.

4.8.5. Figure 4.5. Rescue of FPR-mediated apoptosis by arrestin-2 SH3binding point mutants. A) Arr2-/-/3-/- FPR cells transiently transfected with GFPfused arrestin mutants were assayed for apoptosis. Cells were stained with PI
and 100-300 GFP-expressing cells were viewed and scored for the presence of
PI staining. Data expressed as mean ± SEM PI positive/GFP cell from three
independent experiments. B) Arr-2-/-/-3-/- FPR cells were transiently transfected
with GFP-fused arrestins and incubated with DMSO or PP2 (10nM, 30 min)
before and during stimulation.

4.8.6. Figure 4.6. Internalization of the FPR in presence of arrestin-2 SH3binding point mutants. Arr2-/-/3-/- FPR cells transiently transfected with GFPfused arrestins were stimulated with 1µM fMLF and aliquoted at multiple time
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points. Cells were washed free of fMLF, labeled with 633-6pep and analyzed by
flow cytometry for residual cell surface receptor.

Cells were gated for GFP

expression (FL1) to restrict the analysis to transfected cells. Data are expressed
as the maximum extent of internalization based on curve fitting using a single
exponential decay. Data are expressed as mean ± SEM from three independent
experiments.

4.8.7. Figure 4.7.

Arrestin-2 SH3-binding point mutants traffic normally

with respect to Rab11. Arr2-/-/3-/- FPR cells were transiently transfected with
GFP-fused Rab11 and RFP-fused arrestins and plated on coverslips. Cells were
stimulated with the 633-6pep for 1 hour at 37°C and imaged by confocal
fluorescence microscopy.

Representative images are shown from three

independent experiments.

4.8.8. Figure 4.8.

Arrestin-2 SH3-binding point mutants traffic normally

with AP-2 and AP-1. A) Arr2-/-/3-/- FPR cells were transiently transfected with
RFP-fused arrestins and the GFP-fused α-subunit of AP-2.

Cells were

subsequently stimulated with 633-6pep at 37°C for the indicated time and imaged
by confocal fluorescence microscopy. Representative images are shown from
three independent experiments.

B) Arr2-/-/3-/- FPR cells were transiently

transfected with RFP-fused arrestins and the GFP-fused

-subunit of AP-1.

Cells were then stimulated with the 10nM 633-6pep ligand, fixed and viewed by
confocal fluorescence microscopy. Representative images are shown from three
independent experiments.
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5. SUMMARY, IMPLICATIONS AND
FUTURE DIRECTIONS
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5.1. SUMMARY
In the preceding studies, we sought to identify 1) whether aberrant
signaling causal to FPR-mediated apoptosis in the absence of arrestins was
linked to FPR trafficking defects and 2) which region(s) of arrestin-2 were
responsible for these phenotypes.

Our findings suggest that FPR-mediated

apoptosis and FPR-arrestin trafficking defects are linked with respect to
decreased binding by certain arrestin-2 binding partners. Additionally, we have
done a thorough analysis of arrestin-2 and found that altered binding by certain
accessory proteins (AP-2 and Src kinase) are responsible for these phenotypes.
Finally, we have discovered that arrestin-2 has a new binding partner (AP-1)
whose role in FPR-mediated trafficking and signaling is unknown at this time, but
is under further investigation.

5.1.1. Chapter 2.
Results prior to this work demonstrated that in the absence of arrestins,
FPR activation caused receptor accumulation in the Rab11, perinuclear recycling
endosome (Vines et al., 2003) and initiated apoptosis (Revankar et al., 2004). In
addition, FPR internalization was unaffected, but FPR recycling was inhibited.
These phenotypes were rescued by reconstitution of arrestin-2 or -3 cDNAs. As
arrestin-2 has numerous accessory protein binding partners involved in GPCR
trafficking and signaling (Luttrell and Luttrell, 2003; Luttrell and Luttrell, 2004;
Miller and Lefkowitz, 2001; Pierce and Lefkowitz, 2001; Pierce et al., 2001; Reiter
and Lefkowitz, 2006), we hypothesized that apoptosis and trafficking alterations
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were linked and that specific regions of arrestin-2 were responsible for these
phenotypes.
We first narrowed our search for arrestin-2 regions responsible for these
phenotypes by screening large domains of arrestin-2 for the ability to rescue
FPR-mediated apoptosis.

While none of the domains assayed rescued

apoptosis, only one region was found to bind the activated FPR, arr2-(1-382).
This arrestin-2 mutant is a constitutively active truncation (Krupnick et al., 1997b)
that lacks amino acid residues 383-418. The missing amino acids constitute
numerous binding sites for accessory proteins.

We then used scanning

mutagenesis to generate mutants that had been previously described or change
qualitatively similar amino acids to alanine (Figure 2.2).

When assayed for

apoptosis, all mutants except arr2-F391A and -4A rescued FPR-mediated
apoptosis. Additionally, in the presence of all mutants (except F391A and 4A),
FPR trafficking was unaffected while the F391A and 4A mutants caused FPR
accumulation in the perinuclear recycling endosome.
The F391A mutant had been previously described as having decreased
AP-2 binding and inhibiting β2-AR endocytosis (Milano et al., 2002). The 4A
mutant had not been previously described, but individual mutations (K397A,
M399A and K400A) yielded similar AP-2 binding defects and inhibition of β2-AR
internalization (Kim and Benovic, 2002). Therefore, we hypothesized that FPRarrestin trafficking with AP-2 may be altered.

In confocal fluorescence

microscopy experiments using cells transiently transfected with AP-2-GFP, RFPfused arrestins and stimulated with 633-6pep, FPR-arrestin trafficking was
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indeed altered. In cells expressing wild type arrestin-2, FPR-arrestin trafficking
was normal and AP-2 was colocalized with receptor-arrestin complexes in the
perinuclear region. In cells lacking endogenous arrestins or expressing the
F391A mutant, FPR-arrestin accumulated in the perinuclear recycling endosome
without AP-2 consistent with an inability to bind AP-2. However, in the presence
of the 4A mutant, FPR-arrestin accumulated in the perinuclear region with AP-2.
In addition, AP-2 appeared to colocalize as strongly as or more strongly with the
4A mutant than wild-type arrestin-2.

This was confirmed using co-

immunoprecipitation of FLAG-tagged arrestins after FPR stimulation and looking
for

AP-2

binding.

Our

microscopy

results

were

confirmed:

after

immunoprecipitation with FLAG antibodies, the F391A mutant did not bind AP-2,
wild-type arrestin-2 did bind AP-2 and the 4A mutant bound AP-2 six times as
much as wild-type arrestin-2.
As AP-1 had been previously shown to be necessary for formation of
recycling endosomes (Pagano et al., 2004) and was important to egress from the
Golgi to the cell membrane for certain proteins (Miedel et al., 2006), we
hypothesized it may play a role in efferent FPR trafficking.

Confocal

fluorescence microscopy experiments in cells transiently transfected with AP-1GFP, RFP-fused arrestins and stimulated with 633-6pep showed differential AP-1
trafficking with FPR-arrestin complexes. Without stimulation, AP-1 was localized
to the perinuclear region.

Upon FPR activation, cells lacking arrestins or

expressing the F391A or 4A mutants, FPR-arrestin complexes accumulated with
AP-1 in the perinuclear region. However, in cells expressing wild type arrestin-2,
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FPR-arrestin complexes colocalized with AP-1 in the perinuclear region but FPRarrestin-AP-1 complexes were also seen outside this region consistent with
normal FPR trafficking. We hypothesized that arrestin-2 could bind AP-1 upon
FPR activation and this was confirmed using co-immunoprecipitation assays.
To confirm that receptor-arrestin accumulation in the perinuclear region
was consistent with an inability of the FPR to recycle, we measured FPR
recycling by flow cytometry. While expression of wild type arrestin-2 allowed
FPR recycling, there was virtually no recycling in the presence of the F391A and
4A mutants. To confirm a role for AP-2 and -1 in normal FPR trafficking, we used
siRNA against each in U937 FPR cells (a monocyte cell line that expresses FPR
and both endogenous arrestins) and measured FPR recycling and accumulation
in the perinuclear region. Surprisingly, we found that a decrease in AP-2 levels
inhibited FPR recycling and caused FPR accumulation in the perinuclear region
while decrease of AP-1 levels had no effect.
These findings led to the creation of a model in which after FPR ligand
binding and internalization, arrestin-2 binding occurs followed by AP-2 binding to
arrestin-2.

In the perinuclear recycling endosome, AP-2 must release from

arrestin-2 and only then can FPR-arrestin complexes leave the recycling
endosome and travel back to the cell surface.

Along the latter path, AP-1

interacts with FPR-arrestin, but the physiologic consequences of this binding are
unclear at this time.

Finally, if AP-2 does not bind or release FPR-arrestin

complexes, receptor will be trapped in the recycling endosome and aberrant
signaling complexes will initiate apoptosis.
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5.1.2. Chapter 3.
Previous results by our laboratory have demonstrated that FPR-mediated
apoptosis in the absence of arrestin can be rescued by inhibition of Src kinase,
ERK1/2, JNK3 and p38 MAPKs (Revankar et al., 2004).

It has also been

demonstrated that Src kinase binding to arrestin-2 is necessary for ERK1/2
phosphorylation within the context of β2-AR activation (Luttrell et al., 1999).
Based on these findings, we hypothesized that an arrestin-2 mutant deficient in
Src kinase binding (P91G/P121E) could alter FPR-non genomic signaling and
initiate apoptosis. In apoptosis assays, expression of the P91G/P121E mutant
did not rescue FPR-mediated, but Src kinase inhibition was able to stop
apoptosis. These results indicated that although arrestin-2 and Src kinase have
decreased binding, Src kinase activity can still initiate FPR-mediated apoptosis.
In addition, FPR internalization was not affected by the arrestin-2 mutant or Src
kinase inhibition.
To test the P91G/P121E mutant’s effect on FPR trafficking, we used
confocal fluorescence microscopy. Cells deficient in arrestins were transfected
with RFP-fused arrestins and either Rab11-GFP, AP-2-GFP or AP-1-GFP. Upon
FPR stimulation in the presence of the P91G/P121E mutant, FPR-arrestin
complexes accumulated in the perinuclear recycling endosome with Rab11, AP-2
and AP-1. Because Src kinase inhibition rescued FPR-mediated apoptosis in the
presence of the P91G/P121E mutant, we hypothesized that this inhibition may
rescue the FPR trafficking defects caused by the mutant. To our surprise, this
was not the case. In the presence of PP2, the P91G/P121E mutant accumulated
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with the FPR and Rab11 in the perinuclear recycling endosome. In addition, PP2
caused wild type arrestin-2 to accumulate with the FPR in the Rab11 endosome,
but did not initiate apoptosis. The above results led us to conclude that Src
kinase plays two independent roles when it binds arrestin-2: a role in controlling
FPR-arrestin signaling cascades and a role in FPR-arrestin complex trafficking.
Finally, we hypothesized that if Src kinase cannot bind the P91G/P121E
which results in signaling defects that initiate apoptosis, this might also mean that
ERK1/2 signaling was aberrantly affected. To test this hypothesis, we assayed
apoptosis in the presence of the P91G/P121E mutant and ERK1/2 inhibitors
U0126 and PD98059. Our results demonstrated that in the presence of this
arrestin-2 mutant, ERK1/2 inhibition rescues FPR-mediated apoptosis.

This

indicates that in the absence of Src kinase binding to arrestin-2, not only is Src
kinase signaling aberrantly, but ERK1/2 is as well.
Based on these results, we presented a model for the two independent
actions of Src kinase with respect to arrestin-2 binding. After FPR activation and
internalization, arrestin-2 binds phosphorylated FPR and AP-2 binds arrestin-2.
Upon arrival at the recycling endosome, Src kinase also binds arrestin-2. Src
kinase then phosphorylates AP-2 causing its release from arrestin-2. This has
been previously demonstrated to be integral to internalization of the AT1AR
(Fessart et al., 2005). After AP-2 release, FPR-arrestin can leave the perinuclear
recycling endosome and travel back to the cell surface. However, when the
P91G/P121E mutant binds FPR, AP-2 binds the arrestin mutant, but Src kinase
cannot bind the complex.

The FPR complex accumulates in the recycling

165

endosome and Src kinase signals aberrantly independent of the complex and
initiates apoptosis. Therefore, we conclude that arrestin-independent Src kinase
activity initiates apoptosis, but arrestin-dependent Src kinase activity leads to
normal FPR trafficking and signaling.

5.1.3. Chapter 4.
The results from Chapter 3 demonstrated that Src kinase has two roles in
arrestin-mediated FPR trafficking and signaling. However, this led us to ask an
important question: do FPR trafficking defects lead to FPR signaling defects or
vice-versa? There are three SH-3 binding domains within arrestin-2: P88/P91,
P121/P124 and P175/P178. In our previous work, we used an arrestin-2 mutant
that had contained point mutations within different SH3-binding domains. To
differentiate the effects of different SH3-binding domains on FPR trafficking and
signaling we created three mutants that altered prolines within each SH3-binding
domain (P88A/P91A, P121A/P124A and P175A/P178A).
FPR-mediated apoptosis was rescued by the above arrestin mutants
except P121A/P124A which could only be rescued by Src kinase inhibition. This
implicated the second SH3-binding domain as responsible for Src kinase binding
that rescued FPR-mediated apoptosis. However, when these arrestin-2 mutants
were assayed by confocal fluorescence microscopy for FPR trafficking defects a
surprising result occurred. All mutants trafficked normally with FPR in respect to
Rab11, AP-2 and AP-2 colocalization and FPR internalization was not inhibited.
These results led us to believe that FPR signaling defects could occur in the
absence of FPR trafficking defects.
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In the above results, we used mutants that changed prolines within SH3binding domains to alanine.

We feared that alanine substitutions of multiple

prolines within the same SH3-binding domain may cause different effects on FPR
trafficking and signaling compared to the original mutant used (P91G/P121E).
To alleviate this complication, we made point mutations similar to those used in
Chapter 3, but in one SH3-binding domain at a time (P91G and P121E). In
apoptosis assays, P91G rescued FPR-mediated apoptosis, but the P121E
mutant could not rescue the phenotype. However, apoptosis in the presence of
the P121E mutant was rescuable by Src kinase inhibition. In trafficking assays
using confocal fluorescence microscopy, both mutants trafficked normally with
FPR in correlation with Rab11, AP-2 and AP-1. Once again, FPR internalization
was not affected. These results indicated that our previous results were not the
effect of alanine replacing two prolines in SH3-binding domains of arrestin-2, but
were the result of decreased Src kinase binding to the second SH3-binding
domain (P121/P124) of arrestin-2.
Our results led us to conclude that FPR signaling defects could occur in
the absence of associated trafficking defects.

With respect to Src kinase-

arrestin-2 binding, the second SH3-binding domain (P121/P124) alters FPR
signaling and initiates apoptosis. However, this does not alter FPR trafficking.
Additionally, mutation of the other SH3-binding domains can affect FPR signaling
or trafficking. It is only when the first (P88/P91) and the second (P121/P124)
SH3-binding domains are mutated that both FPR trafficking and signaling are
aberrantly affected.
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5.2. MODEL AND IMPLICATIONS.
5.2.1. Our new model of FPR trafficking and signaling.
Based on our findings in Chapters 2, 3 and 4 and previously published
results, we suggest the following model for the FPR life cycle (Figure 5.1). FPR
is expressed on the cell surface and binds its naturally occurring ligand, fMLF.
This alters the conformation of the receptor, initiating heterotrimeric G protein
EXTRACELLULAR
SPACE

Ligand

GRK
L

PP

MEMBRANE

Receptor

Internalization

L
P

L

G protein

PPP

G protein
signaling

Recycling
vesicle

H+

L
AP-1
AP-2

Phosphatase

L

Arrestin

P PP

L
AP-2

PP

P

NUCLEUS

P

AP-2

MAPK

Src
Src phos of AP-2

Kinase
signaling

Figure 5.1. New model of FPR trafficking and signaling.

binding and activating G protein-mediated signaling pathways. The C-terminus is
then phosphorylated by GRKs. This lowers receptor affinity for G protein binding
and increases its affinity for binding by arrestins effectively desensitizing G
protein signaling. While arrestin may bind FPR at the membrane or in endocytic
vesicles, FPR internalization occurs independently of arrestins, dynamin, clathrin,
AP-2, AP-1 and Src kinase and receptor is transferred to a Rab5-positive, early
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endosome.

Before or during transfer to the Rab11, perinuclear recycling

endosome AP-2 and Src kinase bind the FPR-arrestin complex and initiate non-G
protein, FPR-dependent signaling pathways. In the perinuclear endosome, Src
kinase phosphorylates tyrosine residues on AP-2, causing dissociation of AP-2
from the FPR-arrestin complex. This allows the receptor to leave the recycling
endosome in AP-1-associated vesicles. During its return to the cell surface, the
FPR-arrestin complex dissociates, ligand is uncoupled from receptor and
dephosphorylation of the receptor occurs. After these events, the FPR is once
again expressed on the cell membrane ready to begin the cycle anew.

5.2.2. FPR internalization and that of other GPCRs.
In the previous chapters, we determined that FPR internalization is
independent of arrestins, clathrin, AP-2, AP-1 and Src kinase. Previous reports
have further demonstrated that FPR internalization occurs independently of
dynamin (Gilbert et al., 2001). Our unpublished results also suggest that ADPribosylation factor 6 and the Rho-Rac-Cdc42 pathway are unnecessary for
internalization of the FPR.

An important question raised by these results is:

what regulates internalization of this receptor? Jokingly, we suggest that only
supernatural forces can inhibit FPR internalization. However, in a more serious
manner, we suggest some differences in results and assay design from other
laboratories that may provide insight to this dilemma.
Protein determinants for β2-AR internalization have been well studied and
reviewed.

Currently, β2-AR internalization is demonstrated to be dependent

upon arrestins (Kohout et al., 2001), dynamin (Zhang et al., 1996), Src kinase
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phosphorylation of dynamin (Ahn et al., 1999), clathrin (Goodman et al., 1997),
AP-2 (Laporte et al., 1999) and ADP-ribosylation factor 6 (Claing et al., 2001).
Many GPCRs have internalization pathways which operate independently of
some of these proteins. For example, the m2-muscarinic acetylcholine receptor
internalizes in an arrestin-independent, ADP-ribosylation factor 6-dependent
manner (Pals-Rylaarsdam et al., 1997; Roseberry and Hosey, 2001).

An

interesting point common to these studies is the fact that experiments were all
performed in HEK293 cells. FPR internalization studies in our laboratory have
been performed primarily in MEF or U937 cell lines. It is possible that the cellular
contexts between cell lines used in various studies may allow or inhibit GPCR
use of various internalization pathways and machinery.
Furthermore, our internalization studies use saturating concentrations of
ligand to “flood” the FPR. While this is also true of the aforementioned studies, it
is possible that within our cellular context, multiple avenues of receptor
internalization exist and pathway divergence is used by the FPR under these
high concentrations of ligand. This hypothesis not only explains why we see FPR
internalization occurring independently of so many proteins, but is supported by
interesting results from our laboratory. Unpublished results indicate that use of
lower ligand concentrations during FPR internalization assays has demonstrable
effects on FPR internalization.

When using 1μM fMLF to initiate FPR

internalization, the half-time of internalization is ~90 seconds and the extent of
internalization is ~80-90%. However, when 10nM ligand is used in the same
assays, the rate of FPR internalization is similar with an extent of 20-25% at 10
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minutes that remains constant. This indicates that recycling pathways may be
balancing FPR internalization after 10 minutes. Also, by using 10nM fMLF, only
a fraction of surface FPR is occupied with receptor at the beginning of the
internalization assay leaving open the possibility that under these conditions,
alternative avenues of internalization may not be required. Based on these data,
we suggest that there are multiple internalization pathways for the FPR, and use
of lower ligand concentrations in future experiments may help discovery of the
protein(s) that mediate FPR internalization.

5.2.3.

AP-2 regulates FPR post-endocytic trafficking and trafficking of

other GPCRs.
In our studies, we have shown that AP-2 plays a critical role in FPR postendocytic trafficking. It was demonstrated that both binding and release of AP-2
from arrestin-2 is necessary for it to leave the perinuclear recycling endosome
and return to the cell surface.

Additionally, we hypothesize, based on our

evidence from Chapter 3, that Src phosphorylation of AP-2 may also be
necessary for normal FPR trafficking. The FPR is not the only GPCR for which
AP-2 regulates its trafficking. AT1AR internalization at the cell membrane may be
regulated similarly. One report demonstrated that AP-2 binding to arrestin-2 was
necessary for β2-AR internalization (Laporte et al., 1999).

Furthermore, a

different study examined the regulation of AT1AR internalization by Src kinase
(Fessart et al., 2005).

It was determined that Src kinase phosphorylation of

tyrosine residues on AP-2 was necessary for AP-2 release from arrestin-2 and
subsequent internalization of AT1AR. Given the functional similarity of the two
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receptors (Kim et al., 2005; Shenoy et al., 2006), AP-2-dependent internalization
for the AT1AR is likely. Finally, in a recent report (Mundell et al., 2006), the
authors found that two purinergic receptors, P2Y1 and P2Y12, colocalized with
AP-2 in perinuclear “endocytic compartments”, though the identity of this
compartment was not established.
While the trafficking of individual GPCRs is regulated by AP-2 interactions
at different places within the cell, it is unclear how AP-2 regulates GPCR-arrestin
trafficking. An answer may be found in the differential phosphorylation of GPCRs
after ligand binding and activation. Our laboratory has demonstrated that FPR
phosphorylation patterns by GRKs are highly complex and differentially regulate
receptor desensitization, internalization and arrestin binding (Potter et al., 2006).
For example, the presence of one phosphorylation site in the FPR C-terminus is
adequate to mediate receptor internalization and arrestin binding while the
presence of additional sites of phosphorylation can inhibit arrestin binding without
affecting FPR internalization. Furthermore, exchanging the β2-AR C-terminus for
the V2-vasopressin C-terminus produces a V2-vasopressin receptor trafficking
phenotype upon β2-AR stimulation (Oakley et al., 1999; Oakley et al., 2000).
Finally, differential phosphorylation of AT1AR significantly affected arrestinmediated ERK1/2 activation (Kim et al., 2005).

In this study, GPCR

phosphorylation by GRK4/5 activity, but not GRK2/3 activity, produced ERK1/2
phosphorylation upon receptor activation.
The above studies suggest that different amounts and location FPR
phosphorylation within its C-terminus differentially regulates trafficking and
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signaling.

We suggest that minimal receptor phosphorylation mediates FPR

internalization.

Upon further phosphorylation, perhaps during of after

internalization, arrestin binding occurs.

Finally, after possibly additional

phosphorylation, arrestin binding is sufficient to support binding of AP-2. Due to
similar regulation of the FPR and AT1AR by AP-2 interaction, it is possible to
answer the aforementioned hypothesis by swapping the C-termini of the
receptors and assaying differences in receptor trafficking. We hypothesize that
an FPR/AT1AR C-terminal chimera will traffic similarly to AT1AR upon FPR
stimulation and vice-versa.

5.2.4. Arrestin and Src kinase regulation of FPR signaling.
Throughout our previous studies (Chapters 2-4), we have demonstrated
that proper control of FPR signaling is mediated by arrestins and Src kinase.
Additionally, we have demonstrated that Src kinase binding to arrestin is
necessary for proper regulation of FPR signaling. Finally, we have demonstrated
that the FPR trafficking and signaling defects can be mediated independently of
one another. When cells expressing wild type arrestin-2 are subjected to Src
kinase inhibition with PP2, FPR-arrestin complexes accumulated in the
perinuclear recycling endosome without initiation of apoptosis. On the contrary,
expression of an arrestin mutant deficient in Src kinase binding (P121E) permits
normal FPR-arrestin complex trafficking but initiates apoptosis.
Differential GPCR signaling via arrestin and Src kinase is demonstrated by
the β2-AR and AT1AR (Luttrell et al., 1999). ERK1/2 phosphorylation via β2-AR
activation was inhibited by arrestin mutants that did not bind Src kinase
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(P91G/P121E) or cannot be dephosphorylated (S412D). However, expression of
the arrestin mutant that did not bind Src kinase in the context of AT1AR
stimulation did not alter ERK1/2 signaling. Furthermore, different ligands that
bind the same GPCR can initiate differential activation of ERK1/2. In the context
of CCR7 signaling, CCL19 activates ERK1/2 at early time points and is
subsequently dephosphorylated over time whereas stimulation with CCL21 does
not activate ERK1/2 at all (personal communication, Charlotte Vines, KUMC).
Given the complexity of arrestin regulation of FPR signaling, it is likely that
numerous pathways of MAPK activation and deactivation exist.

In addition,

these pathways may both converge and diverge to control cellular function. More
rigorous examination of these pathways is necessary to understand the effect of
MAPK signaling on FPR trafficking and cellular physiology. These experiments
are further outlined in Future Study 2.

5.3. FUTURE STUDIES.
5.3.1. Future Study 1. Understanding arrestin-2/AP-1 binding.
An interesting finding from Chapter 2, is the discovery that AP-1 binds
arrestin-2 upon FPR activation. While the physiologic effects of this binding are
currently unclear, an understanding of where AP-1 binds arrestin-2 may give us
clues to its function. Currently, amino acids Asp385, Phe388, Phe391, Arg393,
Arg395, Lys397, Met399 and Lys400 in arrestin-2 have all been demonstrated as
binding sites for the β2-subunit of AP-2 (Kim and Benovic, 2002; Milano et al.,
2002). Additionally, amino acids E849, Y888, and E902 within the β2-subunit of
AP-2 are binding sites for arrestin-2 (Laporte et al., 2002). Furthermore, the β1174

subunit of AP-1 shares significant homology with the β2-subunit of AP-2 and the
aforementioned amino acid residues in the β2-subunit are conserved (Lundmark
and Carlsson, 2002).
To better understand where AP-1 and arrestin-2 bind each other, GST
fusions of the critical regions of the β1-subunit containing the aforementioned
amino acid binding sites for arrestin-2 could be used in in vitro binding assays
with wild-type arrestin-2 to discover whether binding could be interrupted upon
amino acid mutation. Furthermore, GST fusions of the β1-subunit could be used
in similar assays with arrestin-2 mutations at sites critical for AP-2 binding.
These assays will determine two important results: 1) whether it is the β1-subunit
that binds arrestin-2 and 2) where the binding sites in the respective proteins are.
These results will give us more data to help determine the role of AP-1/arrestin-2
binding in FPR trafficking and signaling. Alternatively, we may find that it is not
the β1-subunit that binds arrestin-2 or that, in trafficking assays, other proteins
(AP-3 or AP-4) have redundant functions that allow normal FPR trafficking in the
absence of AP-1 binding. Regardless, as this protein-protein interaction is novel
to GPCR trafficking and signaling, data accrued from these experiments will aid
us in elucidating its effects on cellular physiology.

5.3.2. Future Study 2. The effects of aberrant GPCR trafficking on non-G
protein signaling cascades.
Our studies have indicated an intimate association between FPR
trafficking and signaling defects. While these two defects are often linked, it is
possible for each defect to occur independently of the other. In the previous
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chapters, FPR trafficking defects are well documented, whereas FPR signaling
defects are examined by apoptotic signaling and use of signaling protein
inhibitors.

We hypothesize that specific alterations in MAPK phosphorylation

lead to FPR-mediated apoptosis in the absence of arrestins or presence of
arrestin mutants.
To test our hypothesis, we suggest using Western blot analysis of MAPK
phosphorylation patterns. These experiments would be done over a time course
of FPR activation in the absence of arrestins and presence of wild type arrestin-2
or selected arrestin mutants.

Phosphorylation patterns for n-terminal c-jun

kinase 3, p38 and ERK1/2 should be explored. For example, preliminary results
suggests in the absence of arrestins, FPR stimulation leads to early
phosphorylation of ERK1/2, but in the presence of wild type arrestin-2 ERK1/2
has both an early and late phase of phosphorylation. In the presence of an
arrestin mutant that does not bind Src kinase (P91G/P121E), the ERK1/2
phosphorylation pattern is similar to wild type arrestin-2, but is increased at all
time points and is phosphorylated in the absence of ligand stimulation.
Additionally, location of activated MAPKs relative the FPR-arrestin complexes
should be ascertained by confocal immunofluorescence microscopy.

These

experiments may reveal a difference between the levels of MAPK activation and
the possibility of differential location of the activated signaling complexes. The
results of these experiments would lead to an increased understanding of
signaling pathways induced by FPR activation and could be applicable to other
GPCRs of interest.
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5.3.3. Future Study 3. The role of aberrant GPCR trafficking on migration.
It is widely hypothesized, although not directly proven, that inhibition of
GPCR trafficking may lead to defects in cellular migration (Perez et al., 1989;
Perez et al., 1982).

One problem has been the inability to stop

chemokine/chemoattractant receptor trafficking without undue toxicity towards
the cell itself. Our results demonstrate that the FPR accumulates in a perinuclear
region and exhibits impaired recycling in the absence of arrestins or when AP-2
levels are decreased with siRNA. These results give us the ability to address the
role of GPCR trafficking in cellular migration and we hypothesize that when the
FPR traffics abnormally and does not recycle properly, FPR-mediated migration
will be decreased.
To test this hypothesis, we would use U937 cells expressing the FPR.
Then, siRNAs against both arrestin-2 and -3 or AP-2 could be transfected into
cells to decrease the levels of the respective proteins. At this point, any of a
variety of chemotaxis and/or migration assays could be used to monitor the effect
of decreased arrestins or AP-2 on FPR-mediated cell migration.

We could

expect, in either case, that decreased migration in response to fMLF would be
observed.

Additionally, other chemokine/chemoattractant receptors could be

tested in these assays. For example, while CXCR4 stimulation does not initiate
apoptosis in the absence of arrestins (Revankar et al., 2004), CXCR4-mediated
migration of cells is arrestin-dependent (Sun et al., 2002). However, in neither
case was CXCR4 trafficking under their respective conditions examined.
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5.3.4.

Future Study 4.

Rational design of small molecule inhibitors to

interrupt GPCR-arrestin binding.
In previous studies we have found that GPCRs, including the FPR and IL8R, undergo apoptosis upon activation in the absence of arrestins (Revankar et
al., 2004). In addition, we have demonstrated that it is not merely the absence of
arrestins that mediates this phenotype.

On the contrary, FPR-mediated

apoptosis can occur in the presence of arrestin mutants that bind FPR (Chapters
2-4). Based on these results, we suggest that small molecules that interrupt
GPCR-arrestin binding will lead to apoptosis upon stimulation of the respective
GPCR.
To test this hypothesis, we would isolate biotinylated arrestin-2 similar to
that described previously (Potter et al., 2002). Next, we would bind biotinylated
arrestin-2 to streptavidin beads. To ascertain GPCR C-termini binding, purified
FITC labeled, IL-8R or FPR phosphorylated C-termini would be incubated with
the arrestin-bound beads.

When assayed with flow cytometer, the arrestin-

bound beads can be gated using the forward- and side-scatter parameters and
bound FITC-GPCR C-termini can be determined by reading the mean channel
fluorescence in FL1. Then, the same assay can be used with a library of small
molecules to determine which compounds interrupt GPCR-arrestin binding
(mean channel fluorescence decreases in FL1).

After compound screening,

small molecules can be used in cell based assays to determine whether they
alter receptor trafficking and/or initiate apoptosis upon ligand stimulation. This
study would provide us an opportunity to discover small molecules that may be
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able to treat breast cancer metastasis as the IL-8R is known to be involved in this
process (Fournier et al., 2006).

5.3.5.

Future Study 5.

Rational design of small molecule inhibitors to

interrupt AP-2-arrestin binding.
In our work from Chapter 2, we determined that the interaction between
AP-2 and arrestin-2 was integral to normal FPR trafficking and signaling. Altered
interaction between the two proteins led to FPR-arrestin complex accumulation in
the perinuclear recycling endosome and apoptosis. Based on these results, we
hypothesize that small molecules that inhibit the association of AP-2 and arrestin2 may lead to FPR trafficking defects and apoptosis.
To test this hypothesis, we would isolate the GST-tagged β-adaptin
subunit of AP-2 and bind it to glutathione beads. To examine binding of arrestin2 to this subunit, we would incubate the protein-bound beads with purified GFPfused wild type arrestin-2. Similar, to Future Study 4, arrestin binding would be
determined by flow cytometry. Small molecules could then be incubated with the
protein-bound beads and arrestin, to screen for compounds that interrupted the
binding of AP-2 and arrestin-2. From this point, cell based assays could be
employed to determine whether the compound could interrupt AP-2/arrestin
binding in vivo. For example, co-immunoprecipitation, trafficking and apoptosis
assay employed in Chapter 2 could be used to determine the physiologic effect
of screened small molecules. In addition to the use of a compound that disrupted
binding of AP-2 and arrestin-2 to GPCR researchers in general, the compound
could be useful as a chemotherapeutic. For instance, if our hypothesis in Future
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Study 3 was correct, small molecules screened in this study design could be
used to inhibit CXCR4-mediated migration which could be used to treat breast
cancer metastasis.

5.4. Concluding Remarks
In this study, we have made great strides in determining the trafficking and
signaling patterns of the FPR. These results have led to discovery of novel
interactions of AP-2 and AP-1 with arrestin-2 as well as the roles of Src kinase
regulation of FPR trafficking and signaling.

These results pertain to many

GPCRs and will serve as a model for GPCR trafficking and signaling. We have
also proposed numerous future studies that make use of our discoveries to
further understand the implications of arrestins in GPCR migration, trafficking and
signaling. It is our hope that these data and future studies will lead to the design
of novel chemotherapeutics to treat countless patients affected by diseases that
involve dysregulation of GPCR trafficking and signaling.
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